NZ618786B2 - Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides - Google Patents
Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides Download PDFInfo
- Publication number
- NZ618786B2 NZ618786B2 NZ618786A NZ61878612A NZ618786B2 NZ 618786 B2 NZ618786 B2 NZ 618786B2 NZ 618786 A NZ618786 A NZ 618786A NZ 61878612 A NZ61878612 A NZ 61878612A NZ 618786 B2 NZ618786 B2 NZ 618786B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- sulfated
- factor
- nasp
- heparin
- epithelial barrier
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 329
- 230000002708 enhancing Effects 0.000 title claims abstract description 123
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 62
- 150000004676 glycans Polymers 0.000 title claims abstract description 61
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 61
- 150000004804 polysaccharides Polymers 0.000 title claims abstract description 61
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 39
- 230000002429 anti-coagulation Effects 0.000 title claims abstract description 38
- 239000003623 enhancer Substances 0.000 title description 93
- 238000009472 formulation Methods 0.000 title description 4
- 239000000654 additive Substances 0.000 title description 2
- 239000004365 Protease Substances 0.000 claims abstract description 117
- 229920001661 Chitosan Polymers 0.000 claims abstract description 112
- 108010004032 Bromelains Proteins 0.000 claims abstract description 106
- 235000019835 bromelain Nutrition 0.000 claims abstract description 106
- 229920000855 Fucoidan Polymers 0.000 claims abstract description 94
- 229920000669 heparin Polymers 0.000 claims abstract description 75
- 230000023555 blood coagulation Effects 0.000 claims abstract description 58
- 229960002897 Heparin Drugs 0.000 claims abstract description 41
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 39
- 230000002947 procoagulant Effects 0.000 claims abstract description 39
- 239000003805 procoagulant Substances 0.000 claims abstract description 39
- 229960000633 Dextran Sulfate Drugs 0.000 claims abstract description 23
- FCCNSUIJIOOXEZ-SJYYZXOBSA-N Pentosan Polysulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@H](O)CO[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](O)OC1 FCCNSUIJIOOXEZ-SJYYZXOBSA-N 0.000 claims abstract description 22
- 229940043138 Pentosan Polysulfate Drugs 0.000 claims abstract description 22
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 14
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 13
- 150000002482 oligosaccharides Polymers 0.000 claims abstract description 13
- 239000001814 pectin Substances 0.000 claims abstract description 12
- 235000010987 pectin Nutrition 0.000 claims abstract description 12
- 229920001277 pectin Polymers 0.000 claims abstract description 12
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims abstract description 11
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 9
- 150000002402 hexoses Chemical class 0.000 claims abstract description 6
- 150000002972 pentoses Chemical class 0.000 claims abstract description 5
- 206010018987 Haemorrhage Diseases 0.000 claims description 49
- 230000000740 bleeding Effects 0.000 claims description 44
- 231100000319 bleeding Toxicity 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 35
- 102100011311 KNG1 Human genes 0.000 claims description 33
- 206010009802 Coagulopathy Diseases 0.000 claims description 29
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims description 29
- 102100006624 F9 Human genes 0.000 claims description 28
- 108010054218 Factor VIII Proteins 0.000 claims description 25
- 102000001690 Factor VIII Human genes 0.000 claims description 25
- 229960000301 Factor VIII Drugs 0.000 claims description 24
- 108010074864 Factor XI Proteins 0.000 claims description 23
- 108010076282 Factor IX Proteins 0.000 claims description 22
- 229960004222 factor IX Drugs 0.000 claims description 22
- 108010014172 Factor V Proteins 0.000 claims description 21
- 108010071289 Factor XIII Proteins 0.000 claims description 21
- 101710034269 TFPI Proteins 0.000 claims description 21
- 102100008880 TFPI Human genes 0.000 claims description 21
- 229940012444 factor XIII Drugs 0.000 claims description 21
- 201000007368 coagulation protein disease Diseases 0.000 claims description 20
- -1 factor Vlla Proteins 0.000 claims description 20
- 102100009906 F7 Human genes 0.000 claims description 19
- 108010023321 Factor VII Proteins 0.000 claims description 19
- 108010080865 Factor XII Proteins 0.000 claims description 19
- 102000000429 Factor XII Human genes 0.000 claims description 19
- 229940012413 factor VII Drugs 0.000 claims description 19
- 108010014173 Factor X Proteins 0.000 claims description 18
- 108010074860 Factor Xa Proteins 0.000 claims description 18
- 229940012426 factor X Drugs 0.000 claims description 18
- 108010094028 Prothrombin Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 108010056047 Prekallikrein Proteins 0.000 claims description 14
- 108010048049 Factor IXa Proteins 0.000 claims description 11
- 108010000499 Thromboplastin Proteins 0.000 claims description 11
- 102000002262 Thromboplastin Human genes 0.000 claims description 11
- 229960000182 blood factors Drugs 0.000 claims description 10
- 108010074105 Factor Va Proteins 0.000 claims description 9
- 208000008425 Protein Deficiency Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000001154 acute Effects 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 230000001684 chronic Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 claims description 2
- 125000003047 N-acetyl group Chemical group 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940035295 Ting Drugs 0.000 claims 2
- 230000002496 gastric Effects 0.000 abstract description 243
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 124
- 210000001578 Tight Junctions Anatomy 0.000 abstract description 52
- 230000000051 modifying Effects 0.000 abstract description 52
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 28
- 239000000194 fatty acid Substances 0.000 abstract description 28
- 239000003613 bile acid Substances 0.000 abstract description 23
- 150000004665 fatty acids Chemical class 0.000 abstract description 23
- 239000011780 sodium chloride Substances 0.000 abstract description 20
- 150000003839 salts Chemical class 0.000 abstract description 13
- 108091005771 Peptidases Proteins 0.000 abstract description 11
- 229940097362 Cyclodextrins Drugs 0.000 abstract description 5
- 102000035443 Peptidases Human genes 0.000 abstract description 4
- 102100007760 NASP Human genes 0.000 description 105
- 108060005225 NASP Proteins 0.000 description 105
- 239000003114 blood coagulation factor Substances 0.000 description 39
- 241000227647 Fucus vesiculosus Species 0.000 description 38
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 34
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 34
- 210000004027 cells Anatomy 0.000 description 32
- 229940009976 Deoxycholate Drugs 0.000 description 30
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 30
- 229940019700 Blood coagulation factors Drugs 0.000 description 27
- 230000015271 coagulation Effects 0.000 description 25
- 230000001965 increased Effects 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical group [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 21
- 150000002500 ions Chemical class 0.000 description 19
- 230000036912 Bioavailability Effects 0.000 description 17
- 230000035514 bioavailability Effects 0.000 description 17
- 230000035602 clotting Effects 0.000 description 17
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 17
- 210000004369 Blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 108010054265 Factor VIIa Proteins 0.000 description 14
- 229940012414 Factor VIIa Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000000968 intestinal Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 206010010356 Congenital anomaly Diseases 0.000 description 13
- 241001261506 Undaria pinnatifida Species 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 238000004166 bioassay Methods 0.000 description 13
- 230000014508 negative regulation of coagulation Effects 0.000 description 13
- 238000005345 coagulation Methods 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000000981 Epithelium Anatomy 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 206010022114 Injury Diseases 0.000 description 10
- FJCUPROCOFFUSR-GMMZZHHDSA-N maltopentaose Chemical class O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 FJCUPROCOFFUSR-GMMZZHHDSA-N 0.000 description 10
- 208000009292 Hemophilia A Diseases 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 102000033147 ERVK-25 Human genes 0.000 description 7
- 241000195480 Fucus Species 0.000 description 7
- 241000282619 Hylobates lar Species 0.000 description 7
- 210000002381 Plasma Anatomy 0.000 description 7
- 108090001123 antibodies Proteins 0.000 description 7
- 102000004965 antibodies Human genes 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000000977 initiatory Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 102100000368 F8 Human genes 0.000 description 6
- 101700070229 F8 Proteins 0.000 description 6
- 101700074227 F9 Proteins 0.000 description 6
- 108010071241 Factor XIIa Proteins 0.000 description 6
- 108010080805 Factor XIa Proteins 0.000 description 6
- 208000009429 Hemophilia B Diseases 0.000 description 6
- 241000199919 Phaeophyceae Species 0.000 description 6
- 206010043554 Thrombocytopenia Diseases 0.000 description 6
- 206010047715 Von Willebrand's disease Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000003542 factor VIII deficiency Diseases 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241001474374 Blennius Species 0.000 description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 5
- 108010061932 Factor VIIIa Proteins 0.000 description 5
- 229940012952 Fibrinogen Drugs 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 5
- 206010018852 Haematoma Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010029151 Nephropathy Diseases 0.000 description 5
- 206010038428 Renal disease Diseases 0.000 description 5
- 229940083542 Sodium Drugs 0.000 description 5
- 101700048951 VSPDV Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000004059 degradation Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000002255 enzymatic Effects 0.000 description 5
- 230000002008 hemorrhagic Effects 0.000 description 5
- 201000009673 liver disease Diseases 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 230000004797 therapeutic response Effects 0.000 description 5
- 108010047303 von Willebrand Factor Proteins 0.000 description 5
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 4
- 208000002004 Afibrinogenemia Diseases 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010016075 Factor I deficiency Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 4
- 208000002085 Hemarthrosis Diseases 0.000 description 4
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 4
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 4
- 206010021113 Hypothermia Diseases 0.000 description 4
- 101700056073 KNG Proteins 0.000 description 4
- 101700036456 KNG1 Proteins 0.000 description 4
- 108090000563 Lupus Coagulation Inhibitor Proteins 0.000 description 4
- 206010073391 Platelet dysfunction Diseases 0.000 description 4
- WBWWGRHZICKQGZ-HZAMXZRMSA-N Taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 241001261505 Undaria Species 0.000 description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N Ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 4
- 102100019017 VWF Human genes 0.000 description 4
- 206010047634 Vitamin K deficiency Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000004775 coumarins Chemical class 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 230000002631 hypothermal Effects 0.000 description 4
- 239000002722 lupus anticoagulant Substances 0.000 description 4
- 210000004914 menses Anatomy 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 201000007183 prothrombin deficiency Diseases 0.000 description 4
- 238000005670 sulfation reaction Methods 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 201000000839 vitamin K deficiency bleeding Diseases 0.000 description 4
- 229960001134 von Willebrand factor Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3S)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 3
- AJBMORBNKXNZSF-COSHMZDQSA-N (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4 Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS(O)(=O)=O)O4)OC)[C@H](O3)C(O)=O)OC)[C@@H](COS(O)(=O)=O)O2)OS(O)(=O)=O)[C@H](C(O)=O)O1 AJBMORBNKXNZSF-COSHMZDQSA-N 0.000 description 3
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-N-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- KXNPVXPOPUZYGB-XYVMCAHJSA-N Argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 3
- OIRCOABEOLEUMC-GEJPAHFPSA-N Bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- RUDATBOHQWOJDD-BSWAIDMHSA-N Chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 3
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N Dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 3
- 229940093818 Dicumarol Drugs 0.000 description 3
- 241000258955 Echinodermata Species 0.000 description 3
- 241000257465 Echinoidea Species 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 101700042506 HIRUD Proteins 0.000 description 3
- 206010061992 Haemophilia Diseases 0.000 description 3
- 229940006607 Hirudin Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 229960000856 Protein C Drugs 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 229950010535 Razaxaban Drugs 0.000 description 3
- 102100008471 THBD Human genes 0.000 description 3
- 108010079274 Thrombomodulin Proteins 0.000 description 3
- 229960005080 Warfarin Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 229960003856 argatroban Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229960001500 bivalirudin Drugs 0.000 description 3
- 108010055460 bivalirudin Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 229960001912 dicoumarol Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 3
- 229960001318 fondaparinux Drugs 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 108060005018 mobB Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000023 polynucleotide Polymers 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960001522 ximelagatran Drugs 0.000 description 3
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 3
- SRBFZHDQGSBBOR-KKQCNMDGSA-N β-D-xylose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229960005348 Antithrombin III Drugs 0.000 description 2
- 108090000935 Antithrombin-III Proteins 0.000 description 2
- 102000004411 Antithrombin-III Human genes 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 229940009098 Aspartate Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 210000000941 Bile Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229960001091 Chenodeoxycholic Acid Drugs 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102100015239 F2 Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000272496 Galliformes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 229940099347 Glycocholic Acid Drugs 0.000 description 2
- 241000251511 Holothuroidea Species 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N Lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N Potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229940039716 Prothrombin Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229940014499 Ursodeoxycholate Drugs 0.000 description 2
- 229960001661 Ursodiol Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229950001904 chenodiol Drugs 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000000025 haemostatic Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 229920005684 linear copolymer Polymers 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 229940115889 ursodeoxycholic acid Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- PJUIMOJAAPLTRJ-GSVOUGTGSA-N (R)-monothioglycerol Chemical compound OC[C@@H](O)CS PJUIMOJAAPLTRJ-GSVOUGTGSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 240000002254 Ananas comosus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 241000005818 Atherina Species 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229940009025 Chenodeoxycholate Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 241001512723 Ecklonia Species 0.000 description 1
- 229960002852 Ellagic Acid Drugs 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241001631434 Ermia Species 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- GQZXNSPRSGFJLY-UHFFFAOYSA-N Hypophosphorous acid Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 1
- 210000003405 Ileum Anatomy 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000001630 Jejunum Anatomy 0.000 description 1
- 108060005987 Kallikreins Proteins 0.000 description 1
- 102000001399 Kallikreins Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000269774 Lates Species 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001491708 Macrocystis Species 0.000 description 1
- 229940099431 Macrocystis pyrifera extract Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N Myoinositol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 108010049175 N-substituted Glycines Proteins 0.000 description 1
- 229940099990 Ogen Drugs 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940067107 Phenylethyl Alcohol Drugs 0.000 description 1
- 229960002553 Phenylmercuric nitrate Drugs 0.000 description 1
- 229940067605 Phosphatidylethanolamines Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L Potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M Rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M Sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 101700006801 THBI Proteins 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229940046010 Vitamin K Drugs 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 229940019697 Vitamin K containing hemostatics Drugs 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000005114 blood coagulation disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001112 coagulant Effects 0.000 description 1
- 229940105778 coagulation factor VIII Drugs 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic Effects 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 210000004880 lymph fluids Anatomy 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N nitrooxy(phenyl)mercury Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 125000003132 pyranosyl group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003385 sodium Chemical group 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
The disclosure relates to a method of enhancing blood coagulation in a subject, comprising orally administering to the subject a procoagulant amount of a non-anticoagulant sulphated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer comprising chitosan and bromelain in a manner sufficient to enhance blood coagulation in the subject. The NASP may be a naturally occurring NASP selected from the group consisting of N-acetyl-heparin (NAH), N-acetyl-de-O-sulfated-heparin (NA-de-o-SH), de-N-sulfated-heparin (De-NSH), de-N-sulfated-acetylated-he-parin (De-NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan polysulfate (PPS) or fucoidans. The NASP may also be a synthetic NASP selected from the group consisting of sulfated oligomers, sulfated pentoses, sulfated hexoses or sulfated cyclodextrins. The gastrointestinal epithelial barrier permeation enhancer may be a tight junction modulator selected from the group consisting of proteases, bile acids, polysaccharides, fatty acids and salts thereof. The disclosure also relates to a composition comprising the NASP and gastrointestinal epithelial barrier permeation enhancer. n and bromelain in a manner sufficient to enhance blood coagulation in the subject. The NASP may be a naturally occurring NASP selected from the group consisting of N-acetyl-heparin (NAH), N-acetyl-de-O-sulfated-heparin (NA-de-o-SH), de-N-sulfated-heparin (De-NSH), de-N-sulfated-acetylated-he-parin (De-NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan polysulfate (PPS) or fucoidans. The NASP may also be a synthetic NASP selected from the group consisting of sulfated oligomers, sulfated pentoses, sulfated hexoses or sulfated cyclodextrins. The gastrointestinal epithelial barrier permeation enhancer may be a tight junction modulator selected from the group consisting of proteases, bile acids, polysaccharides, fatty acids and salts thereof. The disclosure also relates to a composition comprising the NASP and gastrointestinal epithelial barrier permeation enhancer.
Description
PCT/U52012/047248
RESORPTION ENHANCERS AS ADDITIVES TO IMPROVE THE ORAL
FORMULATION OF NON-ANTICOAGULANT SULFATED POLYSACCHARIDES
CROSS-REFERENCE To RELATED APPLICATION
Pursuant to 35 U .S.C. §119(e), this application claims priority to United States
Provisional Application Serial No. 61/509,514 filed on July 19, 2011, the disclosure of which is
herein incorporated by reference.
UCTION
Bleeding is one of the most serious and significant. manifestations of disease, and may
occur from a local site or be systemic. Localized bleeding may be associated with lesions and
may be further complicated by a defective haemostatic mechanism. Blood clotting is inadequate
in bleeding disorders, which may be caused by ital coagulation disorders, ed
coagulation disorders, or hemorrhagic conditions induced by trauma. Congenital or acquired
deficiencies of any of the coagulation factors may be associated with a hemorrhagic tendency.
Some congenital coagulation disorders include hemophilia, a recessive X-linked disorder
involving a ncy of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) and
von Willebrands disease, a rare bleeding disorder involving a severe ency of von
Willebrands factor. ed coagulation disorders may arise in individuals without a previous
history of bleeding as a result of a disease process. For e, acquired coagulation ers
may be caused by inhibitors or autoimmunity against blood coagulation factors, such as factor
VIII, von Willebrand factor, factors IX, V, XI, XII and XIII; or by hemostatic ers such as
caused by liver disease, which may be associated with decreased synthesis of coagulation factors.
SUMMARY
s of the invention include methods for enhancing blood coagulation in a subject.
In practicing methods according to certain embodiments, an amount of a non-anticoagulant
sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial r
permeation enhancer is orally administered to a subject in a manner sufficient to e blood
coagulation in the subject. Compositions and kits for practicing methods of the invention are
also described.
In embodiments of the invention, an amount of a NASP in ation with a
intestinal epithelial r permeation enhancer is orally administered to a subject in a
manner sufficient to e blood coagulation. In certain ments, the gastrointestinal
epithelial barrier permeation enhancer is a tight junction modulator. For example, tight junction
modulators provided by the invention may include, but are not limited to proteases, bile acids,
WO 12954
polysaccharides, fatty acids and salts f and any combination thereof. For example, the
tight junction modulator may be a bile acid, such as for instance deoxycholate. In other
instances, the tight junction modulator may be a protease, such as bromelain or an tic
ent of bromelain. In yet other instances, the tight junction modulator may be a
polysaccharide, such as chitosan. In still other instances, the tight junction modulator may be a
fatty acid or a fatty acid salt, such as sodium e. In certain embodiments, gastrointestinal
epithelial barrier permeation enhancers of the invention are a combination of tight on
modulators. For example, in certain instances, a combination of bromelain and chitosan are
orally administered with a NASP to a subject in a manner sufficient to enhance blood coagulation
in the subject.
In certain embodiments, the present invention provides a method for ing blood
coagulation by orally administering a composition having an amount of a NASP in ation
with a gastrointestinal epithelial barrier tion enhancer to a subject, where the NASP is a
natural NASP. In some instances, the l NASP is N-acetyl-heparin (NAH), N-acetyl-de—O-
sulfated’heparin (NA-de-o—SH), de-N-sulfated-heparin (De-NSH), de-N—sulfated-acetylated—he-
parin (De-NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL),
chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate
(DXS), heparin-derived oiigosaccharides (HDO), or pentosan polysulfate (PPS). In certain
instances, the natural NASP is a fucoidan. For example, in these embodiments, the an may
be Fucoidan GFS 5508005, Undaria pinnatifida, depyrogenated; Fucoidan GFS 5508004,
Undaria pinnatifida; Fucoidan GFS 3, Undaria pinnatz‘fida; Fucoidan 5307002, Friars
vesiculosus, max. MW peak 126.7 kD; Fucoidan VG49, Fucus vesiculosus, hydrolyzed sample of
2 of lower MW, max. MW peak 22.5 kD; Fucoidan 5308004, Fucus vesiculoxus;
Fucoidan 5308005, Fucus vesiculasus; Fucoidan L/FVF1091, Fucus vesiculosus; Fucoidan
96A, Fucus vesiculosus; Fucoidan VGZOIO96B, Fucus vesiculosus; Fucoidan VG57,
Undaria pinnatifida, high charge (high sulphation, deacetylated); Fucoidan VGSO, Ascophyllum
nodosum, max. MW peak 149.7 kD; and combinations thereof.
In other embodiments, the present invention provides a method for ing blood
coagulation by orally administering a composition having an amount of a NASP in combination
with a gastrointestinal epithelial barrier permeation enhancer to a subject, where the NASP is a
synthetic NASP. For example, the synthetic NASP may be a sulfated er, such as a
sulfated oligosaccharide or a sulfated aliphatic. In certain instances, synthetic NASPs are
sulfated pentoses, sulfated hexoses or sulfated cyclodextrins. For e, synthetic NASPs
may include, but are not limited to sulfated maltopentoses, sulfated beta-cyclodexlrins, sulfated
6-Carboxyicodextrin and derivatives thereof.
In certain embodiments, methods of invention further include orally administering a
blood coagulation factor to the subject in conjunction with the composition containing a
PCTIUS20121047248
procoagulant amount of a NASP in combination with a gastrointestinal epithelial barrier
permeation enhancer. In these instances, the blood coagulation factor may include but are not
limited to factor Xa, factor IXa, factor XIa, factor XIIa, VIIIa, lekrein, and high-molecular
weight kininogen, tissue factor, factor VIIa, factor Va, factor Xa, factor II, factor V, factor VII,
U! factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, von rands factor, and
combinations thereof. For example, in some embodiments, methods of the ion include
orally stering to a subject an amount of a NASP in combination with a gastrointestinal
epithelial r permeation enhancer and factor VIII. In another embodiment, methods include
orally administering to a subject an amount of a NASP in combination with a gastrointestinal
epithelial r permeation enhancer and factor IX.
In other embodiments, the present invention provides a method of inhibiting TFPI
activity in a subject. For example, methods may further include inhibiting TFPI activity in a
subject by orally administering an amount of a NASP in combination with a gastrointestinal
epithelial barrier permeation enhancer in a manner sufficient to inhibit TFPI ty in the
subject. In n instances, a procoagulant amount of a NASP and a gastrointenstinal epithelial
barrier permeation enhancer are combined with a biological sample (e.g., plasma) that includes
TFPI and ing the TFPI activity of the biological sample. In other instances, methods
include combining a procoagulant amount of a NASP and a gastrointestinal epithelial barrier
permeation enhancer with a biological sample, adding TFPI to the composition and measuring
2O TFPI acitivty of the biological .
In certain embodiments, compositions of interest demonstrated ed permeation, for
example, when determined by resorption studies in CaCo-Z cell models as compared to
compositions in the absence of gastrointestinal epithelial permeation enhancers.
ASPECTS OF THE INVENTION
1. A method of enhancing blood coagulation in asubject, the method comprising:
orally administering to the t a procoagulant amount of a non-anticoagulant sulfated
polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation
enhancer in a manner sufficient to enhance blood coagulation in the subject.
3O 2. The method according to Claim 1, wherein the amount of NASP administered to the
subject ranges from 0.01 mg/kg to about 100 trig/kg.
3. The method according to Claim 1, wherein the NASP is a lly occurring or
synthetic NASP.
4. The method according to Claim 3, wherein the NASP is a naturally occurring NASP.
5. The method according to Claim 4, n the naturally occurring NASP is ed
from the group consisting of N-acetyl-heparin (NAH), N—acetyl-de-O-sulfated-heparin (NA-de-o—
PCT/U52012/047248
SH), de-N-sulfated-heparin H), ulfated-acetylated-he- parin (De-NSAH),
periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated
alginic acid (CSAA), chemically sulfated pectin (CSP), dextran e (DXS), heparin-derived
oligosaccharides (HDO), pentosan polysulfate (PPS) and fucoidans, and ations thereof.
6. The method according to Claim 5, wherein the naturally occurring NASP is a fucoidan.
7. The method according to Claim 3, wherein the NASP is a synthetic NASP.
8. The method according to Claim 7, wherein the synthetic NASP is a sulfated oligomer.
9. The method according to Claim 1, wherein the gastrointestinal epithelial barrier
permeation enhancer is a tight junction modulator.
10. The method according to Claim 9, n the tight junction modulator is selected from
the group consisting of proteases, bile acids, polysaccharides, fatty acids and salts f, and
combinations thereof.
11. The method according to Claim 10, wherein the tight junction moldulator ses a
protease.
12. The method according to Claim 11, n the tight junction modulator is bromelain or
an tic component thereof.
13. The method according to Claim 10, wherein the tight on modulator is a bile acid.
14. The method according to Claim 13, wherein the bile acid is deoxycholate.
. The method according to Claim 10, wherein the tight junction modulator is a
polysaccharide.
16. The method according to Claim 15, wherein the polysaccharide is chitosan.
17. The method according to Claim 10, wherein the tight junction modulator is a fatty acid
or salt thereof.
18. The method according to Claim 17, n the tight junction modulator is sodium
caprate.
19. The method according to Claim 1, wherein the gastrointestinal epithelial barrier
permeation enhancer comprises a chitosan and a bromelain.
. The method according to Claim 19, wherein the gastrointestinal epithelial barrier
permeation enhancer comprises about 0.3% to about 3% chitosan and about 0.05 mg/mL to about
3O 0.5 mg/mL bromelain.
21. The method according to Claim 20, wherein the gastrointestinal epithelial barrier
permeation enhancer ses about 3% chitosan and about 0.5 mg/mL bromelain.
22. The method according to Claim 1, wherein the method further comprising administering
to the subject one or more factors selected from the group consisting of factor XI, factor XII,
likrein, high molecular weight kininogen (HMWK), factor V, factor VII, factor VIII, factor
IX, factor X, factor XIII, factor 11, von Willebrands factor, tissue factor, factor VIIa, factor Va,
and factor Xa, factor IXa, factor XIa, factor XIIa, and VIIla.
PCTIUS2012/047248
23. The method according to Claim 1, n the subject has a bleeding er selected
from the group consisting of a chronic or acute bleeding disorder, a congenital coagulation
disorder caused by a blood factor deficiency, and an acquired coagulation disorder.
24. The method Claim 23, wherein the bleeding er is a blood factor deficiency of one
or more factors selected from the group consisting of factor V, factor VII, factor VIII, factor IX,
factor X, factor XI, factor XII, factor XIII, and von Willebrand factor; a fibrinogen disorder; a
ombin disorder; or a platelet dysfunction.
. The method according to Claim 1, wherein the subject is in need of enhanced blood
coagulation e of prior administration of an anticoagulant.
26. The method according to Claim 25, wherein the anticoagulant is selected from the group
consisting of heparin, a coumarin derivative, tissue factor pathway inhibitor (TFPI), antithrombin
III, lupus anticoagulant, nematode anticoagulant peptide (NAPCZ), active-site blocked factor VIIa
(factor VHai), factor IXa inhibitors, factor Xa tor, factor Va inhibitor, factor VIIIa
inhibitor, thrombin inhibitor, and an antibody that binds a clotting factor.
27. The method according to Claim 26, wherein the anticoagulant is an antibody that binds a
clotting factor selected from the group consisting of Factor V, Factor VII, Factor VIH, Factor 1X,
Factor X, Factor XIII, Factor II, Factor XI, Factor XH, von rands factor, prekallikrein, and
high molecular weight kininogen .
28. The method according to Claim 1, wherein the subject is in need of enhanced blood
coagulation because of a al or other invasive procedure.
29. The method according to Claim 1, wherein the method is a method of inhibiting TFPI
activity in the subject.
. An oral dosage composition comprising:
(a) a pro-coagulant amount, of a non—anticoagulant ed polysaccharide
(NASP);
(b) a gastrointestinal epithelial barrier permeation enhancer; and
(c) an oral dosage delivery vehicle;
wherein the oral dosage composition is in unit dosage form.
3]. The oral dosage composition ing to Claim 30, wherein the amount of NASP
3O present in the composition provides a dose in the range of 0.01 mg/kg to about 100 mg/kg.
32. The oral dosage composition according to Claim 30, wherein the NASP is a naturally
ing or synthetic NASP.
33. The oral dosage composition according to Claim 32, wherein the NASP is a naturally
occurring NASP.
34. The oral dosage composition according to Claim 33, wherein the naturally occurring
NASP is selected from the group consisting of N—acetyl-heparin (NAH), N-acetyl-de-O-sulfated-
n -o-SH), de-N-sulfated-heparin (De-NSH), de-N-sulfated-acetylated-he- parin
PCT/US20121’047248
(De-NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically
ed alginic acid , chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-
derived oligosaccharides (HDO), pentosan polysulfate (PPS) and fucoidans, and combinations
thereof.
. The oral dosage composition according to Claim 34, wherein the naturally occurring
NASP is a fucoidan.
36. The oral dosage composition according to Claim 32, wherein the NASP is a tic
NASP.
37. The oral dosage composition according to Claim 36, wherein the tic NASP is a
sulfated oligomer.
38. The oral dosage composition according to Claim 30, wherein the gastrointestinal
epithelial barrier permeation enhancer is a tight junction modulator.
39. The oral dosage composition according to Claim 38, wherein the tight junction
tor is selected from the group consisting of ses, bile acids, polysaccharides, fatty
acids and salts f, and combinations thereof.
40. The oral dosage composition according to Claim 39, wherein the tight junction
moldulator comprises a protease.
41. The oral dosage composition according to Claim 40, wherein the tight on
modulator is bromelain or an enzymatic component f.
42. The oral dosage composition according to Claim 39, n the tight junction
modulator is a bile acid.
43. The oral dosage composition according to Claim 42, wherein the bile acid is
holate.
44. The oral dosage composition according to Claim 39, wherein the tight junction
modulator is a polysaccharide.
45. The oral dosage composition according to Claim 44, wherein the polysaccharide is
chitosan.
46. The oral dosage composition according to Claim 39, wherein the tightjunction
tor is a fatty acid or salt thereof.
47. The oral dosage composition according to Claim 46, wherein the tight junction
modulator is sodium e.
48. The oral dosage composition according to Claim 30, wherein the gastrointestinal
epithelial barrier permeation enhancer comprises a chitosan and a bromelain.
49. The oral dosage composition according to Claim 48, wherein the gastrointestinal
epithelial barrier permeation enhancer comprises about 0.3% to about 3% chitosan and about
0.05 mg/mL to about 0.5 mg/mL bromelain.
50. The oral dosage composition, according to Claim 49, wherein the gastrointestinal
epithelial barrier permeation enhancer ses about 3% chitosan and about 0.5 mg/mL
bromelain.
51. The oral dosage composition according to Claim 30, r comprising one or more
factors selected from the group consisting of factor XI, factor XII, prekallikrein, high molecular
weight kininogen , factor V, factor VII, factor VIII, factor IX, factor X, factor XIII,
factor 11, von Willebrands factor, tissue factor, factor Vila, factor Va, and factor Xa, factor IXa,
factor XIa, factor XIIa, and VIIIa.
52. The oral dosage composition according to Claim 30, wherein the composition is a liquid.
53. The oral dosage composition according to Claim 30, wherein the composition is a solid.
54. Use of a procoagulant amount of a non-anticoagulant sulfated polysaccharide (NASP) in
combination with a gastrointestinal epithelial r permeation enhancer for the manufacture of
a medicament for enhancing blood coagulation in a subject.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the experimental setup for CaC02 bioavailability screening to determine
the % resorption of fucoidans.
Figure 2 shows an example of the amount ofNASP in ation with a
gastrointestinal epithelial barrier permeation enhancer resorbed in CaC02 bioavailability
ing for fucoidan Fucus vesiculosus L/FVF—109l.
Figure 3 shows the condition of the cell layer in the CaCo~2 bioavailability screening for
fucoidan Fucus vesiculosus L/FVFle9l in ation with the gastrointestinal epithelial
barrier permeation er bromelain as measured by transepithelial electrical resistance.
s 4a-b show an example of resorption data acquired in the CaCo~2 bioavailability
screening for fucoidan BAXS 13 in combination with gastrointestinal epithelial barrier
permeation enhancers.
Figures 5a-c show an example of resorption data acquired in the CaCo-Z bioavailability
screening for fucoidan F.v. L/FVF-1091 in combination with intestinal epithelial barrier
permeation enhancers.
Figures 6a-b show an e of resorption data acquired in the CaCo~2 bioavailability
screening for fucoidan U.p. 5508005 in combination with gastrointestinal epithelial barrier
tion enhancers.
Figures 7a-b show an example of resorption data acquired in the CaCo-2 bioavailability
screening for fucoidan F .v.F DSlOOl 108B in ation with gastrointestinal epithelial barrier
permeation ers.
Figures 8a—b show an example of resorption data acquired in the CaCo-2 bioavailability
screening for fucoidan FVF SKl lOl44B in combination with gastrointestinal epithelial barrier
permeation enhancers.
-7A-
PCTfUS2012/047248
Figure 9 show an example of resorption data acquired in the CaCo-Z bioavailability
screening for synthetic NASP sulfated B-cyclodextrin in combination with gastrointestinal
epithelial barrier tion enhancers.
Figure 10 show an example of resorption data acquired in the CaCo—Z bioavailability
screening for synthetic NASP sulfated maltopentaose in combination with gastrointestinal
epithelial barrier tion enhancers.
Figures llaub show show an example of resorption data acquired in the CaCo-Z
bioavailability screening for fucoidans F.v. L/FVF—1091 and F.v.F DSlOOl 108B in combination
with gastrointestinal lial barrier permeation enhancers at g concentrations.
Figures 12a—b shows the condition of the cell layer in the CaCo-2 bioavailability
screening for synthetic NASP sulfated B-cyclodextrin in the absence and in combination with the
gastrointestinal epithelial barrier tion enhancer bromelain as measured by transepithelial
electrical resistance.
Figures l3a—c shows the condition of the cell layer in the CaCo-2 bioavailability
screening for synthetic NASP sulfated maltopentaose in the absence and in combination with the
gastrointestinal epithelial barrier permeation enhancers deoxycholate and chitosan as measured
by transepithelial electrical resistance.
Figures 14a-b show an example of tion data acquired in the CaCo-Z bioavailability
screening for fucoidan B-cyclodextrin in combination with gastrointestinal epithelial barrier
permeation ers.
Figures lSa-b show an example of tion data acquired in the CaCo~2 bioavailability
screening for fucoidan sulfated maltopentaose in combination with gastrointestinal epithelial
barrier permeation enhancers.
RELEVANT DEFINITIONS
In describing the present invention, the ing terms will be employed, and are
intended to be defined as indicated below.
It must be noted that, as used in this specification and the appended , the ar
forms ' a
, an” and “the” include plural referents unless the content clearly dictates otherwise.
3O Thus, for example, reference to a “ NASP” may e a mixture of two or more NASPs, as
desired
An “NASP” as used herein refers to sulfated polysaccharides (SP) that exhibit non-
anticoagulant and anticoagulant activity in any of the various clotting assays described herein.
NASPs may be natural sulfated ccharides, such as those extracted from a biological source
or tic sulfated polysaccharides, where the sulfated polysaccharide is partially or wholly
ed by synthetic methods (e.g., chemical synthesis). One measure of activity is to compare
PCT/U820121047248
the clotting time demonstrated by a NASP with the anticoagulant activity displayed by heparin.
For example, NASPs of interest exhibit anticoagulant activity in the dilute prothrombin time
(dPT) or activated partial mromboplastin time (aPTT) clotting assay that is no more than one-
third, such as less than one-tenth, the molar anticoagulant activity of unfractionated heparin (MW
range 8,000 to 30,000; mean 18,000 daltons). As such, NASPs of st demonstrate a 2-fold
or more lower anticoagulant activity as compared to heparin, such as a 5-fold or more lower
anticoagulant ty as compared to heparin, such as a 10-fold or more lower agulant
activate as compared to heparin, such as a 25—fold or more lower anticoagulant activity as
compared to heparin, such as a 50-fold or more lower anticoagulant activity as compared to
heparin, including a lOO-fold or more lower anticoagulant activity as compared to heparin, by
ing methods and compositions as ed herein.
NASPs of interest may range in molecular weight from 10 daltons to 1,000,000 daltons,
such as for example, from 100 daltons to 900,000 daltons, such as from 500 daltons to 500,000
s, such as from 1000 s to 250,000 daltons, including 5000 daltons to 150,000
daltons. NASPs may range in average molecular weight from about 10 daltons to about 500,000
daltons, such as from about 100 daltons to about 0 daltons, such as from 1000 daltons to
250,000 daltons, including 1000 daltons to 150,000 daltons.
In some instances, NASPs of st may include, but are not limited to yl-
heparin (NAH), N-acetyl-de-O-sulfated-heparin -o-SH), de-N-sulfated-heparin (De-
2O NSH), de-N-sulfated-acetylated-he- parin (De-NSAH), periodate-oxidized heparin (POH),
chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically
sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived accharides (HDO), pentosan
polysulfate (PPS), sulfated maltopentoses, sulfated beta-cyclodextrins, sulfated 6-
Carboxyicodextrin and derivatives thereof. In certain instances, the NASP is a fucoidan. For
example, the an may be Fucoidan 5307002, Fucus vesiculosus, max. MW peak 126.7 kD;
Fucoidan VG49, Fucus losus, yzed sample of 5307002 of lower MW, max. MW
peak 22.5 kD; Fucoidan V657, Undaria pinnan‘fida, high charge (high sulphation, deacetylated);
Fucoidan GFS (5508005), Undaria pinnatifida, genated; Fucoidan GFS (L/FVF—0109l),
Fucus vesiculosus, depyrogenated, max. MW peak 125 kD; Fucoidan GFS (L/FVF-01092),
3O Fucus vesiculosus, depyrogenated, max. MW peak 260 kD; Fucoidan GFS (L/FVF-01093),
Fucus vesiculosus, hydrolyzed depyrogenated, max. MW peak 36 kD; Maritech® Ecklonia
radiala t; Maritech® Ecklorzz’a maxima extract; Maritech® Macrocystis pyrifera extract;
Maritech® Immune trial Fucoidan Blend; and combinations thereof.
NASPs in combination with a gastrointestinal epithelial barrier permeation enhancer may
be used in the methods of the invention for improving hemostasis, in treating bleeding disorders,
such as those associated with deficiencies of coagulation s or for reversing the effects of
anticoagulants, in particular when enhanced resorption by the gastrointestinal system is necessary
PCT/U52012/047248
or desired. The ability of NASPs to promote clotting and reduce ng may be ined
using various in vitro clotting assays (e.g., TFPI-dPT, thrombin generation and
thromboelastography (TEG) assays) and in vivo bleeding models (ag. tail snip, transverse cut,
whole blood clotting time, or cuticle bleeding time determination in hemophilic mice or dogs).
U! See, e.g., PDR Staff. Physicians' Desk Reference. 2004, Anderson et a1. (1976) Thromb. Res.
9:575-580; Nordfang et al. (1991) Thromb Haemost. 66:464-467; Welsch et a1. (1991)
Thrombosis Research -222; Broze et al. (2001) Thromb Haemost 851747-748; Scallan et
a1. (2003) Blood. 102:2031-2037; Pijnappels et al. (1986) Thromb. Haemost. 55:70-73; and Giles
et al.(1982) Blood 601727-730, and the examples herein.
A “procoagulant” is used herein in its conventional sense to refer to
any factor or reagent
capable of initiating or accelerating clot formation. A procoagulant of the invention includes but
is not limited to any activator of the sic or extrinsic coagulation pathways, such as a clotting
factor selected from the group consisting of factor Xa, factor IXa, factor Xla, factor X1121, and
VIlIa, prekallelqein, high-molecular weight gen, tissue factor, factor Vita, and factor Va,
as well as other reagents that promote clotting e kallikrein, APTT initiator (i. e., a t
containing a phospholipid and a contact activator), Russel‘s viper venom (RVV time), and
thromboplastin (for dPl‘). In some embodiments, t activators may be employed as
procoagulant reagents. For example, t tors may include micronized silica particles,
ellagic acid, sulfatides, kaolin or the like. Procoagulants may be from a crude natural t, a
blood or plasma sample, isolated and substantially purified, synthetic, or recombinant.
Procoagulants may include naturally occurring clotting factors or fragments, variants or
covalently modified derivatives thereof that retain biological activity (116., promote clotting).
The term “polysaccharide,” as used herein, refers to a polymer containing two or more
covalently linked saccharide es. Saccharide residues may be linked for e by
glycosidic, ester, amide, or oxime linking moieties. The average molecular weight of
polysaccharides may vary widely, such as for example ranging from 100 to 1,000,000 daltons
and more, such as 100 to 500,000 daltons and more, such as 1000 to 250,000 s and
more,
such as 1000 to 100,000 s and more, such as 10,000 to 50,000 daltons and more.
Polysaccharides may be straight chained (i.e., linear) or branched or may contain discrete regions
3O of linear and branched portions. Polysaccharides may also be fragments of polysaccharides
generated by degradation (e.g., hydrolysis) of larger polysaccharides. Degradation can be
achieved by any convenient protocol including treatment of polysaccharides with acid, base,
heat, oxidants or enzymes to yield fragmented polysaccharides. Polysaccharides may be
chemically altered and may be modified, including but not limited to, sulfation, polysulfation,
esterification, and methylation.
lar weight, as discussed herein, can be sed as either a number average
molecular weight or a weight average molecular weight. Unless otherwise indicated, all
references to lar weight herein refer to the weight average molecular weight. Both
molecular weight determinations, number average and weight average, can be measured using
for e, gel tion chromatography or other liquid chromatography techniques.
The term “derived from” is used herein to fy the original source of a molecule but
is not meant to limit the method by which the molecule is made which can be, for example, by
chemical synthesis or recombinant methodologies.
The terms “variant,39 nanalog” and “mutein” refer to biologically active derivatives of a
reference le, that retain desired activity, such as clotting activity in the treatment of a
bleeding disorder. The terms “variant” and “analog” in reference to a polypeptide (e.g., clotting
) refer to compounds having a native polypeptide sequence and structure with one or more
amino acid additions, substitutions (generally conservative in nature) and/or ons, ve to
the native molecule, so long as the modifications do not destroy biological activity and which are
“substantially homologous” to the reference molecule as defined below. The amino acid
sequences of such analogs will have a high degree of sequence homology to the reference
sequence, e.g., amino acid sequence homology of 50% or more, such as 60% or more, such as
70% or more, such as 80% or more, such as 90% or more, such as 95% or more, including 99%
or more when the two sequences are aligned. In some instances, analogs will include the same
number of amino acids but will include substitutions. The term “mutein” further es
ptides having one or more amino acid-like molecules including but not limited to
compounds contain only amino and/or imino molecules, polypeptides containing one or more
s of an amino acid (including, for example, synthetic turally occuring amino acids,
etc.), ptides with substituted linkages, as well as other modifications known in the art, both
naturally occurring and non—naturally ing (e. g., tic), cyclized, branched molecules
and the like. The term also includes molecules comprising one or more N-substituted glycine
residues (a “peptoid”) and other tic amino acids or peptides. (See, e.g., US. Patent Nos.
,831,005; 5,877,278; and 5,977,301; Nguyen et al., Chem Biol. (2000) 7:463—473; and Simon et
al., Proc. Natl. Acad. Sci. USA (1992) 89:9367—9371 for descriptions of peptoids). In
embodiments of the invetion, analogs and muteins have at least the same clotting activity as the
native molecule.
3O As discussed above, analogs may include substitutions that are conservative, i.e., those
substitutions that take place within a family of amino acids that are related in their side chains.
cally, amino acids are generally divided into four families: (1) acidic -- aspartate and
glutamate; (2) basic -- lysine, arginine, histidine; (3) non-polar -- alanine, valine, leucine,
isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar -- glycine,
asparagine, glutamine, ne, serine threonine, tyrosine. Phenylalanine, tryptophan, and
tyrosine are in some instances classified as aromatic amino acids. For example, an isolated
replacement of leucine with isoleucine or valine, an aspartate with a glutamate, a threonine with a
PCT/U82012/047248
, or a r conservative ement of an amino acid with a structurally related amino
acid, will not have a major effect on the biological activity. For example, the polypeptide of
interest may include up to about 5-10 conservative or non-conservative amino acid substitutions,
or even up to about 15-25 conservative or non—conservative amino acid substitutions, or any
U! integer between 5-25, so long as the desired function of the molecule remains .
By “derivative” is meant any suitable modification of the reference molecule of interest
or of an analog thereof, such as sulfation, acetylation, glycosylation, phosphorylation, polymer
ation (such as with polyethylene glycol), or other addition of n moieties, so long as
the desired biological activity (6.3., clotting activity, inhibition of TFPI activity) of the reference
molecule is retained. For example, polysaccharides may be derivatized with one or more organic
or inorganic groups. Examples include but are not d to polysaccharides substituted in at
least one hydroxyl group with another moiety (e. g., a sulfate, carboxyl, phosphate, amino, nitrile,
halo, silyl, amido, acyl, aliphatic, aromatic, or a saccharide , or where a ring oxygen has
been replaced by , nitrogen, a methylene group, etc. Polysaccharides may be chemically
altered, for example, to improve procoagulant function. Such modifications may include, but are
not limited to, sulfation, polysulfation, esterification, and methylation.
By “fragment” is meant a molecule containing a part of the intact full-length sequence
and ure. In some instances, a fragment of a polysaccharide may be generated by
degradation (e.g., hydrolysis) of a larger polysaccharide. Active fragments of a polysaccharides
of the invention may include about 2-20 saccharide units of the full-length polysaccharide, such
as about 5-10 saccharide units of the full—length molecule, and including any integer between 2
saccharide units and the full-length molecule, so long as the fragment retains biological activity,
such as for example, ng activity or the ability to inhibit TFPI activity. A fragment of a
polypeptide can include a C-terminal deletion, an N-terminal deletion, or an internal deletion of
the native polypeptide. Active fragments of a particular protein may include, in some
embodiments, about 5—10 contiguous amino acid es of the full-length molecule or more,
such as about 1525 contiguous amino acid residues of'the full-length molecule or more, such as
about 20-50 contiguous amino acid residues of the full—length molecule or more, and including
any r between 5 amino acids and the full—length sequence, so long as the fragment in
question retains biological activity, such as for example, clotting activity.
By “substantially purified” is meant the isolation of a substance (e.g., non-anticoagulant
sulfated polysaccharide) such that the substance includes the ty of the sample in which it
s. For example, a sample that is ntially purified contains 50% or more of the
substance of interest, such as 60% or more of the substance of interest, such as 75% or more of
3S the substance of interest, such as 90% or more of the substance of interest, such as 95% or more
of the substance of interest, including 99% or more of the substance of interest. Any convenient
protocol may be ed for ing ccharides, polynucleotides, and polypeptides of
PCT/U820121047248
interest and include, but are not limited to ultrafiltration, selective precipitation, llization,
ion-exchange chromatography, affinity chromatography and ntation according to density.
By “isolated” is meant, when, referring to a ccharide or polypeptide, that the
indicated molecule is separate and discrete from the whole sm with which the molecule is
found in nature or is present in the substantial e of other biological macro-molecules of the
same type.
By ogy” is meant the percent identity between two polypeptide moieties. As
referred to herein, two polypeptide sequences are antially homologous” to each other when
the sequences exhibit about 50% or more sequence identity, such as 60% or more
sequence
identity, such as 75% or more sequence identity, such as 85% or more sequence identity, such as
90% or more sequence identity, such as 95% or more sequence identity, including 99% or more
sequence identity. In some embodiments, substantially homologous polypeptides include
sequences having complete identity to a specified sequence.
By ity” is meant an exact t to subunit correspondence of two polymeric
sequences. For example, an identical polypeptide is one that has an exact amino acid-to-amino
acid pondence to another ptide or an identical polynucleotide is one that has an
exact nucleotide-to-nucleotide correspondence to another polynucleotide. Percent identity can be
determined by a direct ison of the sequence information between two molecules (the
2O reference sequence and a sequence with unknown % identity to the reference sequence) by
aligning the ces, counting the exact number of matches between the two aligned
sequences, dividing by the length of the reference sequence, and multiplying the result by 100.
Any convenient protocol may be employed to determine percent identity between two polymeric
sequences, such as for example, ALIGN, Dayhoff, MO. in Atlas of Protein Sequence and
Structure M.O. Dayhoff ed., 5 Suppl. 35353-358, National biomedical Research Foundation,
Washington, DC, which adapts the local homology algorithm of Smith and Waterman Advances
in Appl. Math. 22482—489, 1981 for e analysis.
By “subject” is meant any member of the subphylum chordata, including, without
limitation, humans and other primates, including non—human es such as chimpanzees and
other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses;
domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats
and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and
other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age.
Thus, both adult and newborn individuals are of st.
The term "patient," is used in its conventional sense to refer to a living organism
suffering from or prone to a condition that can be prevented or treated by administration of a
NASP 0f the invention, and includes both humans and non-human animals.
By “biological sample” is meant a sample of tissue or fluid ed from a subject,
including but not limited to, for example, blood, plasma, serum, fecal matter, urine, bone
marrow, bile, spinal fluid, lymph fluid, samples of the skin, external secretions of the skin,
respiratory, inal, and genitourinary tracts, tears, saliva, milk, blood cells, organs, biopsies
and also samples of in vitro cell culture constituents including but not limited to conditioned
media resulting from the growth of cells and tissues in culture medium,
e.g., recombinant cells,
and cell components.
By “therapeutically effective dose or amount” is meant an amount that, when
administered as described herein, brings about the d therapeutic response, such as for
example, reduced bleeding or shorter clotting times.
By “bleeding disorder” is meant any disorder associated with excessive bleeding, such as
a congenital coagulation er, an acquired coagulation disorder, administration of an
anticoagulant, or a trauma induced hemorrhagic ion. As discussed below, bleeding
disorders may include, but are not limited to, hemophilia A, hemophilia B, von Willebrand
disease, thic ocytopenia, a deficiency of one or more t factors, such as Factor
XI, Factor XII, prekallikrein, and high lar weight kininogen (HMWK), a deficiency of
one or more factors ated with clinically significant bleeding, such as Factor V, Factor VII,
Factor VIII, Factor IX, Factor X, Factor XIII, Factor II (hypoprothrombinemia), and von
rands factor, a vitamin K deficiency, a disorder of fibrinogen, including afibrinogenemia,
hypofibrinogenemia, and dysfibrinogenemia, an alphaZ-antiplasmin deficiency, and excessive
bleeding such as caused by liver disease, renal disease, thrombocytopenia, et dysfunction,
hematomas, internal hemorrhage, hemarthroses, surgery, trauma, hypothermia, menstruation, and
pregnancy.
DETAILED DESCRIPTION
Aspects of the invention include methods for enhancing blood coagulation in a subject.
In cing methods according to n embodiments, an amount of a non—anticoagulant
sulfated polysaccharide (NASP) in combination with a‘ gastrointestinal epithelial barrier
permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood
coagulation in the subject. Compositions and kits for practicing methods of the invention are
also described.
Before the invention is described in r detail, it is to be understood that the
invention is not d to particular embodiments described herein as such embodiments may
vary. It is also to be understood that the terminology used herein is for the purpose of describing
U.) U1 particular ments only, and the terminology is not intended to be limiting. The scope of the
invention will be limited only by the appended claims. Unless defined otherwise, all technical
and scientific terms used herein have the same meaning as commonly understood by one of
ry skill in the art to which this ion belongs. Where a range of values is provided, it is
understood that each intervening value, to the tenth of the unit of the lower limit unless the
context clearly dictates otherwise, n the upper and lower limit of that range and
any other
stated or ening value in that stated range, is encompassed within the invention. The
upper
and lower limits of these smaller ranges may independently be included in the smaller
ranges and
are also encompassed within the invention, subject to any specifically excluded limit in the stated
range. Where the stated range includes one or both of the limits, ranges excluding either or both
of those included limits are also included in the invention. Certain ranges are presented herein
with numerical values being preceded by the term " about. " The term "about“ is used herein to
provide literal support for the exact number that it precedes, as well as a number that is near to or
approximately the number that the term precedes. In determining whether a number is near to or
approximately a specifically recited number, the near or approximating unrecited number may be
a number, which, in the context in which it is presented, provides the substantial equivalent of the
specifically d . All publications, patents, and patent applications cited in this
specification are incorporated herein by reference to the same extent as if each dual
publication, , or patent application were specifically and individually indicated to be
incorporated by reference. Furthermore, each cited publication, patent, or patent application is
incorporated herein by reference to disclose and be the subject matter in connection with
which the publications are cited. The citation of any publication is for its disclosure prior to the
filing date and should not be construed as an admission that the invention described herein is not
entitled to antedate such publication by virtue of prior ion. Further, the dates of publication
provided might be different from the actual publication dates, which may need to be
independently med.
It is noted that the claims may be drafted to exclude any optional element. As such, this
statement is intended to serve as antecedent basis for use of such exclusive terminology as
"solely, n «only," and the like in connection with the recitation of claim elements, or use of a
"negative" limitation. As will be nt to those of skill in the art upon reading this disclosure,
each of the individual embodiments described and rated herein has discrete components and
features which may be readily separated from or combined with the features of
any of the other
l embodiments without departing from the scope or spirit of the invention. Any recited
method may be carried out in the order of events recited or in any other order that is logically
possible. Although any methods and materials similar or equivalent to those described herein
may also be used in the practice or testing of the invention, representative illustrative methods
and materials are now described.
In r describing the subject invention, s for ing blood coagulation in a
subject by orally administering a NASP in combination with a gastrointestinal epithelial barrier
tion er are described first in greater detail. Next, compositions and kits for
practicing methods of the t invention are also bed.
METHODS FOR ENHANCING BLOOD COAGULATION IN A SUBJECT
As summarized above, aspects of the invention include methods for enhancing blood
coagulation by orally administering a composition having an amount of a NASP in ation
with a gastrointestinal epithelial permeation enhancer to a subject. The term “enhancing blood
coagulation” is used in its conventional sense to refer to accelerating the initiation (i.e., reducing
the amount time for coagulation to begin) of blood coagulation as well as the overall rate of
blood coagulation of the subject (i.e., ng the amount of time for blood coagulation to be
complete). In some embodiments, methods of the invention accelerate the initiation of blood
coagulation. For example, methods of the invention may reduce the amount of time required for
the blood to begin coagulating by 5% or more, such as by 10% or more, such as by 25% or more,
such as by 50% or more, such as by 75% or more, such as by 90% or more, such as 95% or more,
as compared to a suitable control. In other embodiments, methods of the invention increase the
rate of blood coagulation. For example, methods of the invention may increase the rate of blood
coagulation by 2% or more, such as by 5% or more, such as by 10% or more, such as by 25% or
more, such as by 50% or more, such as by 75% or more, such as by 100% or more, such as by
200% or more, including by 500% or more, as compared to a suitable control.
In embodiments of the present disclosure, a procoagulant amount of a NASP is orally
administered in combination with a gastrointestinal epithelial barrier permeation enhancer.
ing on the physiology of the subject, the phrase “gastrointestinal epithelial” as used
, refers to the epithelial tissue of the digestive tract, such as the stomach and intestinal tract
(e.g,, duodenum, jejunum, ileum), and may further include other structures which participate in
the gastrointestinal functions of the body including the lower part of the esophagus, the rectum
and the anus. By gastrointestinal permeation enhancer is meant a compound that, when orally
administered, increases the amount of NASP that is resorbed by the gastrointestinal .
Furthermore, gastrointestinal permeation enhancers may also accelerate the initiation (i.e.,
reducing the amount time for resorption to begin) of NASP resorption through the
3O gastrointestinal epithelium as well as accelerate the l rate of ort of the NASP across
the gastrointestinal epithelium of the t (i.e., reducing the amount of time for NASP
resorption by the gastrointestinal system to be complete).
In some embodiments, gastrointestinal epithelial barrier permeation enhancers increase the
amount of NASP resorbed by the intestinal system. For e, gastrointestinal epithelial
barrier permeation enhancers may increase the amount of NASP resorbed by the gastrointestinal
system by 5% or more, such as by 10% or more, such as by 25% or more, such as by 50% or
~16-
PCT/U82012/047248
more, such as by 75% or more, such as by 90% or more, such as 95% or more, as compared to a
le control. In other embodiments, gastrointestinal epithelial barrier permeation ers
accelerate the initiation of NASP resorption through the gastrointestinal epithelium. For
example, gastrointenstinal lial barrier permeation ers of the invention may reduce
the amount of time required to initiate resorption of the NASP by 5% or more, such as by 10% or
more, such as by 25% or more, such as by 50% or more, such as by 75% or more, such as by
90% or more, such as 95% or more, as compared to a suitable control. In yet other embodiments,
gastrointestinal epithelial r permeation enhancers of the invention increase the rate of
resorption of the NASP by the intestinal system. For example, gastrointestinal epithelial
barrier permeation enhancers may increase the rate of NASP resorption by 2% or more, such as
by 5% or more, such as by 10% or more, such as by 25% or more, such as by 50% or more, such
as by 75% or more, such as by 100% or more, such as by 200% or more, including by 500% or
more, as compared to a suitable control. In some instances, gastrointestinal epithelial
tion enhancers of the invention may increase the tion of NASPs as determined by
Caco-2 cell models, as described in greater detail below. For example, gastrointestinal epithelial
barrier permeation enhancers of the invention may increase the resorption as determined by
Caco-Z cell models by 2% or more, such as by 5% or more, such as by 10% or more, such as by
% or more, such as by 50% or more, such as by 75% or more, such as by 100% or more, such
as by 200% or more, including by 500% or more, as compared to a suitable control.
In embodiments of the invention, gastrointestinal epithelial barrier permeation enhancers
may vary, depending on the ular blood coagulation disorder, the physiology of the subject and
the desired enhancement of resorption by the gastrointestinal . In some embodiments,
gastrointestinal epithelial barrier tion enhancers are tight junction modulators. The term
“tight junction” is employed in it conventional sense to refer to the closely associated cellular areas
where membranes of adjacent cells are joined together. As such, in certain embodiments, methods of
the invention include orally administering a composition having a procoagulant amount of a NASP in
combination with a compound which modulates the permeation of the NASP through the tight
junctions of the gastrointestinal epithelium. By “modulates” is meant modifying or increasing the
permeation of the NASP through the tight junctions of the gasnointestinal epithelium. As such, tight
3O junction modulators modify or increase the resorption of NASPs by the gastrointestinal . In
embodiments of the ion, tight on modulators may include, but are not limited to
enzymes,
bile acids, ccharides, fatty acids and salts thereof and any combination thereof.
In some instances, tight junction tors are polysaccharides. For example, the
polysaccharide tight junction modulator may be chitosan. Chitosan, as used herein refers to the
linear copolymer of 2-acetarnidedeoxy-l3-D-glucopyranose and o-[3-D~glucopyranose
produced by the N-deactylation of chitin. Polysaccharide tight junction modulators may also include
tives of chitosan such as N-alkyl chitosan, acylated chitosan, thiolated chitosan,
PCT/U320121047248
phosphorylated chitosan, chitosan cyclodextrin, N-(aminoalkyl) chitosan, succinyl chitosan and
octanoyl chitosan, among others.
In other instances, tightjunction modulators are bile acids. The term “bile acid” is used in its
conventional sense to refer to the steroidal acids and salts thereof commonly found in the bile of
’Jl mammals. Suitable bile acids may include, but are not limited to, cholic acid (cholate), deoxycholic
acid (deoxycholate), chenodeoxycholic acid (chenodeoxycholate), ursodeoxycholic acid
(ursodeoxycholate), glycocholic acid (glycocholate), taurocholic acid (taurocholate) and holic
acid cholate), among others.
In other instances, tight junction modulators are s. For example, the enzyme tight
junction modulators may be a protease, such as bromelain or an enzymatic fragment of bromelain.
Bromelain, as used herein refers to the group of enzymes commonly derived from the fruit, stem and
leaves of Ananas s and may also include elements such as cysteine proteases, amylase, acid
phosphatase, peroxidases and cellulases.
In yet other instances, tight junction modulators are fatty acids and fatty acid salts f.
Fatty acid tight junction modulators of the invention may vary, and may include any one or a
combination of medium chain fatty acids, such as for e C8 (caprylate), C10 (caprate) and C12
(laurate) fatty acids and fatty acid salts f. In certain instances, for example, the fatty acid tight
junction modulator is sodium caprate.
The concentration of gastrointestinal epithelial barrier permeation enhancer that is
stered in combination with the NASP may vary depending on the effects as desired.
Depending on the gastrointestinal epithelial barrier permeation enhancer, the concentration may
be 0.01% or more of the total mass of the composition, such as 0.1% or more, such as 1% or
more, such as 2% or more, such as 5% or more, such as 10% or more, such as 15% or more, such
as 20% or more, such as 25% or more and including 50% or more of the total mass of the
composition. In other embodiments, the concentration of the gastrointestinal epithelial barrier
permeation er that is administered in combination with the NASP is 0.01 mg/mL or more,
such as 0.05 mg/mL or more, such as 0.1 mg/mL or more, such as 1 mg/mL or more and
including 5 mg/mL or more. In yet other ments, the concentration of the gastrointestinal
epithelial barrier permeation enhancer that is administered in combination with the NASP is 0.1
mM or more, such as 0.5 mM or more, such as 1 mM or more, such as 5 mM or more, such as 10
mM or more, such as 25 mM or more and including 50 mM or moreln certain ments, two
or more gastrointestinal epithelial barrier permeation enhancers are employed concurrently. For
example, two or more tight junction modulators may be employed in combination with a NASP,
such as three or more tight junction modulators, including four or more tight on
modulators. Any combination of tight junction modulators may be employed, such as for
example, a polysaccharide and a protease, a fatty acid and polysaccharide, a ccharide and
a bile acid, a polysaccharide, a fatty acid and a bile acid, two different polysaccharides or two
-18—
PCT/U82012/047248
different bile acids, among other combinations. Where more than one gastrointestinal epithelial
barrier permeation enhancer is employed, the mass tage of each gastrointestinal epithelial
barrier permeation enhancer may vary, ranging from 1% or more of the total mass of the
composition, such as 2% or more, such as 5% or more, such as 10% or more, such as 25% or
U] more and including 50% or more of the total mass of the composition. For example, where two
gastrointestinal lial barrier permeation enhancers are employed, the mass ratio of the first
gastrointestinal epithelial barrier permeation er and the second intestinal epithelial
barrier permeation enhancer may vary, g between 1:1 and 1:25; 1:25 and 1:5; 1:5 and
1:10; 1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and 1:150; 1:150 and 1:200; 1:200 and
1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range thereof. For example, the mass ratio of the
first gastrointestinal epithelial barrier permeation enhancer to the second gastrointestinal
epithelial barrier permeation enhancer may range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and
1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000. In some embodiments, the mass
ratio of the second gastrointestinal epithelial barrier permeation er to the first
gastrointestinal epithelial r permeation enhancer ranges between 1:1 and 1:25; 1:2.5 and
and 1:10; 1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and 1:150; 1:150 and
1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and 121000, or a range thereof. For example, the
mass ratio of the second gastrointestinal epithelial barrier permeation enhancer to the first
gastrointestinal epithelial barrier permeation enhancer may range between 1:1 and 1:10; 1:5 and
1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000. In certain instances,
the gastrointestinal epithetial barrier permeation enhancer includes a chitosan and
a bromelain.
Where a chitosan and a bromelain are employed, the mass ratio of the chitosan and the bromelain
may vary, ranging between 1:] and 122.5; 1:25 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and
1:50; 1:50 and 1:100; 1:100 and 1:150; 1:150 and 1:200;1:200 and 1:250; 1:250 and 1:500;
1:500 and 1:1000, or a range thereof. For e, the mass ratio of the chitosan to the
bromelain may range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50
and 1:500; or 1:100 and 1:1000. In some embodiments, the mass ratio of the ain to the
chitosan ranges between 1:1 and 112.5; 1:25 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and 1:50;
1:50 and 1:100; 1:100 and 1:150; 1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and
3O 1:1000, or a range thereof. For example, the mass ratio of the bromelain to the chitosan
range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or
1:100 and 1:1000.
Where a combination of chitosan and ain are ed, in certain embodiments,
the concentration of an may vary, ranging from about 0.1% to about 5%, such as about
0.15% to about 4.5%, such as 0.2% to about 4%, such as about 0.25% to about 3.5%, such as
0.3% to about 3%, such as 0.5% to about 2.5%, including about 0.5% to 1.5%. Likewise, where
a combination of chitosan and bromelain are employed, in certain embodiments, the
W0 2013/012954
concentration of bromelain may vary, ranging from about 0.01 mg/mL to about 1.0 mg/mL, such
as about 0.2 mg/mL to about 0.9 mg/mL, such as 0.25 mg/mL to about 0.75 mg/mL, such as
about 0.3 mg/mL to about 0.6 mg/mL, including about 0.4 mg/mL to about 0.5 mg/mL. As such,
in these embodiments, methods include administering a NASP in combination with both chitosan
and bromelain. For example, the NASP may be a natural or synthetic NASP, such as those
bed above, including N-acetyl-heparin (NAH), N—acetyl-de-O-su1fated-heparin (NA-de—o—
SH), de-N—sulfatedheparin (De—NSH), de-N-sulfated-acetylated~he— parin (De-NSAH),
periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated
alginic acid (CSAA), chemically ed pectin (CSP), dextran sulfate (DXS), heparin-derived
oligosaccharides (HDO), pentosan polysulfate (PPS), ed maltopentoses, sulfated beta-
cyclodextrins, sulfated 6-Carboxyicodextrin and tives thereof. For instance, the NASP
may be a fucoidan, such as an 5307002, Fucus vesiculosus, max. MW peak 126.7 kD;
Fucoidan VG49, Fucus vesiculosus, hydrolyzed sample of 5307002 of lower MW, max. MW
peak 22.5 kD; Fucoidan VG57, Undaria pinnatifida, high charge (high sulphation, deacetylated);
Fucoidan GFS (5508005), Undaria pinnatifida, depyrogenated; Fucoidan GFS (L/FVF~01091),
Fucus vesiculosus, depyrogenated, max. MW peak 125 kD; Fucoidan GFS -01092),
Fucus vesiculosus, genated, max. MW peak 260 kD; Fucoidan GFS (L/FVF-01093),
Fucus losus, hydrolyzed depyrogenated, max. MW peak 36 kD; Maritech® ia
radiata t; Maritech® Ecklom'a maxima extract; Maritech® Macrocysti: pyriflra extract;
Maritech® Immune trial Fucoidan Blend; and combinations thereof. As noted above, in certain
instances the concentration of chitosan ranges from about 0.1% to about 5%, such as about 3%
and the concentration of bromelain ranges from 0.1 mg/mL to about 1 mg/mL, such as about 0.5
mg/mL.
Where two or more gastrointestinal epithetial barrier permeation enhancers are
employed, in some embodiments, the combination is a synergistically effective combination of
gastrointestinal epithetial barrier permeation enhancers. The term “synergistically effective” is
meant that the combination of gastrointestinal epithetial barrier permeation enhancers produces
an effect (i.e., es intestinal epithelial barrier permeation) which is greater than
would be achieved by the sum of the individual gastrointestinal epithetial barrier permeation
enhancers. For example, the combination of more than one intestinal epithelial barrier
permeation enhancer produces an effect that is 2-fold or greater than would be achieved by the
sum of the individual gastrointestinal epithelial r permeation enhancers, such as 3—fold or
greater, such as 4-fold or greater, such as 5-fold or greater, such as 10-fold or greater and
including d or greater than would achieved with the sum the individual gastrointestinal
epithelial barrier permeation ers. As such, where two gastrointestinal epithelial barrier
permeation enhancers are ed, synergistically effective combinations of the present
invention produce an effect which is 2-fold or greater, such as 5-fold or greater, such as 10-fold
or greater and including 25 ~fold or greater than would be achieved by the sum of the two
individual gastrointestinal epithelial barrier permeation enhancers. Likewise, where three
gastrointestinal epithelial barrier permeation enhancers are combined, synergistically ive
combinations of the present invention produce an effect which is 2—fold or greater, such as 5-fold
or greater, such as IO-fold or greater and including 25-fold or greater than would be achieved by
the sum of the three individual gastrointestinal epithelial barrier permeation enhancersln certain
embodiments, synergistically effective combinations of the present invention include a
ation of chitosan and ain. In these embodiments, the combination of chitosan and
bromelain has a greater effect on enhancing permeation through the gastrointestinal epithelial
r than is achieved by the sum of chitosan and bromelain individually. For example, in
some ces, the combination of chitosan and bromelain enhances permeation through the
gastrointestinal epithelial barrier by 2—fold or r, such as 5-fold or greater, such as 10-folder
or greater and ing 25 -fold or greater than is achieved by the sum of chitosan and bromelain
individually. In certain instances, synergistically effective combinations include a combination
of bromelain having a concentration ranging from 0.l mg/mL to about 0.5 mg/mL, such as 0.15
mg/mL to about 0.4 mg/mL, including 0.25 mg/mL and an having a concentration ranging
from about 1% to about 5% w/v, such as 1.5% to about 4.5% w/v, such as 2% to about 4% w/v
and including about 3% w/v. In certain embodiments, istically effective combinations of
bromelain and an include a ation of 0.5mg/mL ain and 3% wiv chitosan. In
other embodiments, istically effective combinations of bromelain and chitosan include
0.25 mg/mL bromelain and 1.5% w/v chitosan. In yet other embodiments, synergistically
effective combinations of bromelain and chitosan include 0.12 mg/mL bromelain and 0.75% w/v
chitosan.
In embodiments of the ion, methods for enhancing blood coagulation by orally
administering a NASP in combination with a gastrointestinal epithelial barrier permeation
enhancer to a subject are provided. By “subject” is meant the person or organism ing the
blood coagulation enhancement. As such, subjects of the ion may include but are not
limited to humans and other primates, such as chimpanzees and other apes and monkey species;
farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and
cats; laboratory s including rodents such as mice, rats and guinea pigs; birds, including
domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks,
geese, and the like.
In some embodiments, the t methods may be employed to treat bleeding disorders,
such as a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood
factor deficiency, an acquired coagulation disorder and administration of an anticoagulant. For
example, bleeding disorders may include, but are not limited to hemophilia A, hemophilia B, von
Willebrand disease, idiopathic thrombocy‘topenia, a deficiency of one or more contact factors,
PCT/U52012/047248
such as Factor XI, Factor XII, prekallikrein, and high molecular weight lcininogen (HMWK), a
deficiency of one or more factors associated with clinically significant bleeding, such as Factor
V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor II (hypoprothrombinemia),
and von Willebrands factor, a vitamin K deficiency, a disorder of fibrinogen, including
U! afibrinogenemia, hypofibrinogenemia, and rinogenemia, an alphaz-antiplasmin deficiency,
and excessive bleeding such as caused by liver disease, renal disease, thrombocytopenia, platelet
dysfunction, hematomas, internal hemorrhage, hroses, surgery, , hypothermia,
menstruation, and pregnancy.
In other embodiments, the subject methods may be employed to e blood
coagulation in order to reverse the effects of an anticoagulant in a subject. For example, the
t may have been treated with an anticoagulant including, but not limited to, heparin, a
coumarin derivative, such as warfarin or dicumarol, TFPI, AT III, lupus anticoagulant, nematode
anticoagulant peptide (NAPcZ), active-site blocked factor VIIa (factor VIIai), factor IXa
inhibitors, factor Xa inhibitors, including fondaparinux, idraparinux, DX-9065a, and razaxaban
(DPC906), tors of s Va and VIIIa, including activated protein C (APC) and e
thrombomodulin, thrombin tors, including hirudin, bivalirudin, argatroban, and
ximelagatran. In certain embodiments, the anticoagulant in the subject may be an antibody that
binds a clotting factor, including but not limited to, an antibody that binds to Factor V, Factor
VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor II, Factor XI, Factor XII, von
Willebrands factor, prekallilqein, or high molecular weight gen (HMWK).
Aspects of the invention e orally administering to a subject a composition having
an procoagulant amount of a NASP in combination with a gastrointestinal epithelial barrier
permeation enhancer to enhance blood coagulation. As described above, NASPs of the invention
may be l NASPs or synthetic NASPs. In some embodiments, NASPs are natural NASPs.
By “natural” is meant that the NASP is found or derived from a naturally occurring source, such
as from an animal or plant source and encompass a broad range of subclasses including heparins,
glycosarninoglycans, fucoidans, carrageenans, pentosan polysulfates, dermatan sulfates and
dextran sulfates. In some embodiments, natural NASPS may be extracted from a biological
3O source. By “biological source” is meant a lly-occurring organism or part of an sm.
For example, NASPs of interest may be extracted from plants, animals, fungi or bacteria. In
ular, NASPs of interest may be extracted from edible seaweeds, brown algae, echinoderms
(e.g., sea urchins, sea ers) and the like. Any convenient protocol can be employed for
extracting the NASP from the biological source. For ce, the NASP can be extracted from
the biological source by acid-base extraction, enzymatic degradation, selective precipitation,
filtration, among other procedures. Methods for extracting and isolating NASPs from biological
sources such as edible seaweeds and brown algae are described in detail in co-pending US.
W0 2013/012954 PCT/U82012/047248
Patent Application Serial No. ,712, filed February 25, 2010, the disclosure of which is
herein incorporated by reference, in its entirety.
In certain ments, natural NASPs of the invention include, but are not d to
N-acetyl-heparin (NAH), yl—de—O-sulfated-heparin (NA-de-o-Sl—l), ulfated-heparin
(De-NSH), de—N-sulfated-acetylated~he- parin (De-NSAH), periodate-oxidized heparin (POH),
chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically
sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan
polysulfate (PPS) and ations thereof. In some instances, the NASP may be a low
lar weight fragment of a naturally occurring NASP. In other instances natural NASPs
may also include biochemical or chemical derivatives of naturally occurring NASPs. In certain
instances, natural NASPs are fucoidans. As described in greater detail below, fucoidans are
naturally-occurring complex sulfated polysaccharides compounds which may be extracted from
certain edible ds, brown algae and derms (e.g, sea s, sea ers). As
used herein the term, “fucoidan” refers to a diverse group of moieties ted from a biological
source of low e polymers rather than a single chemical entity. In certain instances,
fucoidans of the invention include, but are not limited to Fucoidan GFS 5508005, Undaria
pinnatifida, depyrogenated; Fucoidan GFS 5508004, Undaria pinnatilida; Fucoidan GFS
5508003, Undaria pinnatifida; Fucoidan 5307002, Fucus vesiculosus, max. MW peak 126.7 kD;
Fucoidan VG49, Fucus vesiculosus, hydrolyzed sample of 5307002 of lower MW, max. MW
2O peak 22.5 kD; Fucoidan 5308004, Fucus vesiculosus; Fucoidan 5308005, Fucus vesiculosus;
Fucoidan L/FVF1091, Fucus vesiculosus; Fucoidan VC1201096A, Fucus vesiculosus; Fucoidan
96B, Fucus vesiculosus; Fucoidan VG57, Undaria pinnatifida, high charge (high
sulphation, deacetylated); Fucoidan VGSO, Ascophyllum nodosum, max. MW peak 149.7 kD;
and combinations thereof.
Examples of suitable NASPs are described in greater detail in United States Patent
Application Serial No. 11/140,504, filed on May 27, 2005, now United States Patent No.
7,767,654, and United States Patent Application Serial No. 13/006,396, filed on Januaryl3,
2011, the disclosures of which is herein orated by reference in their entirety.
In other embodiments, NASPs are synthetic NASPs. By “synthetic” is meant that the
sulfated polysaccharide is partially or wholly produced by man-made methods (cg, chemical
synthesis). For e, the synthetic NASP may be a sulfated oligomer, such as a sulfated
oligosaccharide or a sulfated tic. In certain instances, synthetic NASPs are ed
es, sulfated hexoses or sulfated cyclodextrins. For example, synthetic NASPs may
include, but are not limited to sulfated maltopentoses, sulfated beta-cyclodextrins, sulfated 6-
Carboxyicodextrin and derivatives thereof.
Examples of other suitable synthetic NASPs are described in greater detail in United
States Provisional Patent Application Serial No. 61/592,554, filed on January 30, 2012 and
PCTI’U320121047248
United States Provisional Patent Application Serial No. 61/592,549, filed on y30, 2012,
the disclosures of which is herein incorporated by reference in their entirety.
Depending on the desired s and potency of the NASPS, one or more NASPS may
employed together. For example, two or more NASPs may be employed together, such as three
or more NASPs and including four or more NASPs. Where more than one NASP is employed,
all of the NASPs may be natural NASPs, all of the NASPs may be synthetic NASPS or any
combination thereof. Where more than one NASP is employed, the mass percentage of each
NASP in the composition may vary, ranging from 1% or more of the total mass of the
composition, such as 2% or more, such as 5% or more, such as 10% or more, such as 25% or
more and including as 50% or more of the total mass of the composition.
In embodiments of the ion, the mass ratio of the NASP and the gastrointestinal
epithelial barrier permeation er may vary, ranging between 1:1 and 1:2.5; 122.5 and 1:5;
1:5 and 1:10; 1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and 1:150; 1:150 and mm;
1:200 and 1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range thereof. For example, the mass
ratio of the NASP to the gastrointestinal epithelial barrier permeation enhancer may range
between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and
1:1000. In some embodiments, the mass ratio of the gastrointestinal epithelial barrier
permeation enhancer to the NASP ranges between 1:1 and 1:25; 1:2.5 and 1:5; 1:5 and 1:10;
1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and 1:150; 1:150 and 1:200; 1:200 and
1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range thereof. For example, the mass ratio of the
gastrointestinal epithelial barrier permeation enhancer to the NASP may range between 1:1 and
:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000.
The NASP and the gastrointestinal epithelial barrier permeation enhancer may be
stered to the subject in any order. In some instances, the NASP is orally administered
prior to orally administering the gastrointestinal epithelial barrier permeation enhancer. In other
instances, the NASP is orally administered after orally administering the gastrointestinal
epithelial r permeation enhancer. In yet other instances, the NASP is orally administered in
conjunction with orally administering the gastrointestinal epithelial barrier permeation enhancer.
If both the NASP and the gastrointestinal epithelial barrier permeation enhancer are provided at
the same time, each can be provided in the same or in a different composition. Where the NASP
and the gastrointestinal epithelial barrier tion enhancer are administered at the same time,
the NASP may be mixed with the gastrointestinal epithelial r tion enhancer the
blood ation factor before stering the composition to the subject. Any convenient
mixing protocol may be used, such as by dry shaking, on or suspension mixing, industrial
mixing protocols and the like. Thus, NASPs and gastrointestinal epithelial barrier permeation
enhancers can be presented to the individual by way of concurrent therapy. By “concurrent
therapy” is ed administration to a subject such that the therapeutic effect of the
WO 12954
combination of the NASP and gastrointestinal epithelial barrier permeation enhancer is caused in
the subject oing therapy. Similarly, one or more NASPs and one or more gastrointestinal
epithelial barrier permeation ers can be orally administered in at least one therapeutic
dose.
U] Any suitable ation of NASP and gastrointenstinal epithelial barrier tion
enhancer may be administered. In n embodiments, s include administering a natural
NASP (as described above) with one or more of intenstinal epithelial barrier permeation
enhancers. In these ments, methods may include administering a combination of a natural
NASP with one or more of sodium caprate, deoxycholate, bromelain and an. In certain
embodiments, methods include administering a natural NASP with sodium caprate. For instance,
one or more of Undaria pinnatifida U.p.5508005 and Fucus vesiculosus Ev. L/FVF 1091 may be
administered with sodium caprate. In other embodiment, methods include administering a
natural NASP with deoxycholate. For instance, one or more of Undaria pinnatifida
U.p.5508005, Fucus losus Ev. L/FVF 1091, Fucus vesiculosus Ev. D81001108, Fucus
vesiculosus Ev. SK110144B may be stered with deoxycholate. In yet other embodiments,
methods include administering a natural NASP with bromelain. For instance, one or more of
Undarz‘a pinnatifida U.p.5508005, Fucus vesiculosus Ev. L/FVF 1091, Fucus vesiculosus Ev.
DSlOOl 108, Fucus vesiculosus Ev. SK110144B may be administered with bromelain. In yet
other embodiments, methods include stering a natural NASP with chitosan. For instance,
one or more of Undaria pinnatifida U .p.5508005 Fucus vesiculosus Ev. L/FVF 1091, Fucus
vesiculosus Ev. DSlOOl 108, Fucus vesiculosus F.v. SK110144B
may be administered in
combination with chitosan. In yet other embodiments, methods include administering a l
NASP with a combination of bromelain and chitosan( as described above). For instance, one or
more of Undaria pinnatifida U.p.5508005, Fucus lasus Ev. L/FVF 1091, Fucus
vesiculosus Ev. DSIOOI 108, Fucus vesiculosus Frv. SKl 10144B
may be administered with a
combination of bromelain and chitosan.
In certain embodiments, methods e administering a synthetic NASP (as described
above) with one or more of gastrointenstinal epithelial r permeation enhancers. In these
embodiments, methods may include administering a combination of a synthetic NASP widl one
or more of sodium caprate, deoxycholate, bromelain and chitosan. In certain embodiments,
methods include administering a synthetic NASP with sodium caprate. For instance, one or more
of a sulfated B-cyclodextrin and a sulfated maltopentose may be administered with sodium
caprate. In other embodiment, methods include administering a tic NASP with
deoxycholate. For instance, one or more of a 24 kD sulfated 6-carboxyicodextrin, a 14 kD 6-
carboxyicodextrin, a sulfated B—cyclodextrin and a sulfated maltopentose may be administered
with deoxycholate. In yet other embodiments, methods include administering a synthetic NASP
PCT/U82012/047248
with bromelain. For instance, one or more of a 24 kD sulfated 6-carboxyicodextrin, a 14 kD 6-
carboxyicodextrin, a sulfated B-cyclodextrin and a sulfated maltopentose may be administered
with bromelain. In yet other ments, methods include administering a synthetic NASP
with an. For instance, one or more of a 24 kD sulfated 6-carboxyicodextrin, a 14 kD 6—
carboxyicodextrin, a sulfated B-cyclodextrin and a sulfated maltopentose may be administered in
combination with chitosan. In yet other embodiments, methods include administering a tic
NASP with a combination of bromelain and chitosan( as described above). For instance, one or
more of a 24 kD sulfated 6-carboxyicodextrin, a 14 kD, 6-carboxyicodextrin, a sulfated B-
cyclodextrin and a sulfated maltopentose may be administered with a combination of bromelain
and chitosan.
In certain embodiments, aspects of the invention include enhancing blood coagulation in
a subject by orally administering to the subject, a composition that contains a procoagulant
amount of a NASP and a intestinal lial r permeation er in ation
with a blood coagulation factor. For example, the subject may be orally administered a
procoagulant amount of a composition containing a NASP and a gastrointestinal epithelial barrier
tion enhancer in combination with one or more blood coagulation factors which include,
but are not limited to factor XI, factor XII, prekallikrein, high molecular weight kininogen
(HMWK), factor V, factor VII, factor VIII, factor IX, factor X, factor XIII, factor II, factor VIIa,
and von Willebrands factor, factor Xa, factor [Xa, factor Xla, factor XIla, and VIIIa,
prekallekrein, and high-molecular weight kininogen, tissue factor, factor VIIa, factor Va, and
factor Xa.
Where a composition that contains a NASP and a gastrointestinal epithelial barrier
tion enhancer is orally administered with a blood coagulation factor to the subject, the
mass ratio of the composition that contains the NASP and gastrointestinal epithelial barrier
Ix) U! permeation enhancer to the blood coagulation factor may vary, ranging between 1:1 and 122.5;
122.5 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and 1150;1250 and 1:100; 1:100 and 1:150;
1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range f. For
example, the mass ratio of the composition that contains the NASP and intestinal epithelial
barrier permeation enhancer to the blood ation factor may range between 1:1 and 1:10; 1:5
and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000. In some
embodiments, the mass ratio of the blood coagulation factor to the composition that contains the
NASP and gastrointestinal epithelial barrier permeation enhancer ranges between 1:1 and 1:25;
122.5 and 1:5; 1:5 and 1:10;1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and 1:150;
1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and , or a range thereof. For
example, the mass ratio of the blood coagulation factor to the ition that contains the
PCT/U82012i047248
NASP and gastrointestinal epithelial barrier permeation enhancer
may range between 1:1 and
1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000.
The blood coagulation factor and the composition that contains the NASP and
gastrointestinal epithelial barrier permeation enhancer may be administered to the t in any
order. In some instances, the composition that contains the NASP and gastrointestinal epithelial
barrier permeation enhancer is orally administered prior to administering the blood coagulation
factor In other instances, the composition that contains the NASP and gastrointestinal epithelial
r permeation enhancer is orally administered in ction with administering the blood
coagulation factor. In yet other ces, the ition that contains the NASP and
gastrointestinal epithelial barrier permeation enhancer is orally administered after administering
the blood coagulation factor. Where the composition that contains the NASP and gastrointestinal
epithelial barrier permeation enhancer is orally administered in conjunction with the blood
coagulation , the composition that contains the NASP and gastrointestinal epithelial barrier
permeation enhancer may be mixed with the blood coagulation factor before orally administering
the composition to the subject. Any convenient mixing protocol
may be used, such as a by dry
shaking, solution or suspension mixing, industrial mixing ols and the like.
Aspects of the invention include methods and compositions for treating bleeding
disorders by orally administering a gulant amount of a NASP in combination with
gastrointestinal epithelial r permeation enhancer. NASPs in ation with a
gastrointestinal epithelial barrier permeation enhancer as disclosed herein can be administered
alone (i.e., as single agents), or in combination with other hemostatic
agents. As desired, a
procoagulant amount of a NASP in combination with a gastrointestinal epithelial barrier
permeation enhancer may be employed in the treatment of a subject that has been diagnosed as
having a bleeding disorder, including congenital coagulation disorders, acquired coagulation
ers, administration of an anticoagulant, and trauma d hemorrhagic conditions.
In some ces, a subject may be diagnosed as having a blood clotting disorders that
includes, but is not d to hemophilia A, hemophilia 13, von Willebrand disease, idiopathic
thrombocytopenia, a ency of one or more contact factors, such as Factor XI, Factor XII,
prekallikrein, and high molecular weight kininogen (HMWK), a deficiency of one or more
factors associated with clinically significant bleeding, such as Factor V, Factor VII, Factor VIII,
Factor IX, Factor X, Factor XIII, Factor II (hypoprothrombinemia), and von Willebrands factor,
a vitamin K deficiency, a disorder of ogen, including afibrinogenemia, rinogenemia,
and inogenemia, an alphaz-antiplasmin deficiency, and excessive bleeding such as caused
by liver disease, renal disease, thrombocytopenia, platelet dysfunction, hematomas, internal
hemorrhage, hemarthroses, surgery, trauma, ermia, uation, and pregnancy,
In other instances, a subject may be diagnosed as having a blood clotting disorder that
includes a congenital coagulation disorder or an acquired coagulation disorder caused by a blood
PCT/U52012/047248
factor deficiency. For example, the blood factor deficiency may be caused by deficiencies of one
or more factors, including but not limited to, factor V, factor VII, factor VIII, factor IX, factor
XI, factor XII, factor XIII, and von Willebrand factor.
In yet other instances, a subject may be diagnosed as having a blood clotting disorder
resulting from the administration of an anticoagulant to the subject. For example, the
anticoagulant may include but is not d to, heparin, a coumarin derivative, such as warfarin
or dicumarol, tissue factor pathway inhibitor , antithrombin III, lupus anticoagulant,
nematode anticoagulant peptide (NAPc2), active-site blocked factor VIIa (factor VIIai), factor
lXa inhibitors, factor Xa inhibitors, including fondaparinux, idraparinux, DX—9065a, and
razaxaban 6), inhibitors of factors Va and Villa, ing activated protein C (APC) and
soluble thrombomodulin, in inhibitors, including hirudin, bivalirudin, argatroban, and
ximelagatran. In certain embodiments, the anticoagulant may be an antibody that binds a ng
factor, including but not limited to, an dy that binds to Factor V, Factor VII, Factor VIII,
Factor IX, Factor X, Factor XIII, Factor II, Factor XI, Factor XII, von Willebrands factor,
prekallikrein, orhigh molecular weight kininogen (HMWK).
In yet other instances, methods of the invention include a method of inhibiting TFPI
activity in a subject. For example, methods may further include orally administering to a subject,
an amount of a NASP in combination with a intestinal lial barrier permeation
enhancer in a manner sufficient to inhibit TFPI activity in the t. In certain instances, a
procoagulant amount of a NASP in combination with a gastrointenstinal epithelial barrier
permeation enhancer is combined with a biological sample (e.g., blood plasma) that includes
TFPI and measuring the TFPI ty of the biological sample. In other instances, methods
e combining a procoagulant amount of a NASP and a gastrointestinal epithelial r
permeation er with a biological sample, adding TFPI to the composition and measuring
the TFPI acitivty of the biological sample. In certain instances, the biological sample is a plasma
, such as for e, normal blood plasma or Factor VIII-inhibited blood .
In practicing methods of the invention, protocols for enhancing blood coagulation in a
subject may vary, such as for example by age, weight, severity of the blood clotting disorder, the
general health of the subject, as well as the ular composition and concentration of the
3O NASPs and gastrointestinal epithelial barrier permeation enhancers being administered. In
embodiments of the invention, the concentration of NASPs achieved in a subject following oral
administration and resorption by the gastrointestinal system may vary, in some instances, ranging
from 0.01 nM to 500 nM. NASPs of interest are procoagulant at their optimal concentration. By
“optimal concentration” is meant the concentration in which NASPS exhibit the highest amount
of procoagulant activity. Since many of the NASPs also demonstrated anticoagulant activity at
much higher concentrations than the optimal tration, NASPs of the invention show non-
anticoagulant behavior in the range of its optimal concentration. As such, depending on the
-28—
potency of the NASP as well as the desired effect, the optimal concentration of NASPS provided
by methods of the invention may range, from 0.01nM to 500 nM, such as 0.1 nM to 250 nM,
such as 0.1 nM to 100 nM
, such as 0.1 nM to 75 nM, such as 0.1 nM to 50 nM, such as 0.1 nM
to 25 nM, such as 0.1 nM to 10 nM, and including 0.1 nM to 1 nM. Optimal concentrations and
activity level as determined by calibrated automated thrombography (CAT) assay of NASPs of
interest are described in greater detail in United States Patent Application Serial No. 11/140,504,
filed on May 27, 2005, now United States Patent No. 7,767,654, and United States Patent
ation Serial No. 13/006,396, filed on yl3, 2011, the disclosures of which is herein
incorporated by reference in their entirety. se, the concentration of gastrointestinal
epithelial barrier permeation enhancers achieved in a subject following oral administration and
resorption by the gastrointestinal system may vary, in some instances, ranging from 0.01 nM to
500 nM. For example, depending on the inherent absorptivity of the NASP as well as the desired
effect, the concentration of intestinal epithelial barrier permeation enhancers provided by
methods of the invention may range, from 0.0lnM to 500 nM, such as 0.1 nM to 250 nM, such
0.1 nM to 100 nM
, such as 0.1 nM to 75 nM, such as 0.1 nM to 5011M, such as 01 nM to 25
nM, such as 0.1 nM to 10 nM, and ing 0.1 nM to 1 nM.
Therefore, the oral dosage of compositions containing NASPs in combination with
gastrointestinal epithelial barrier permeation enhancers of interest may vary, ranging from about
0.01 mg/kg to 500 mg/kg per day, such as from 0.01 mg/kg to 400 mg/kg
per day, such as 0.01
mg/kg to 200 mg/kg per day, such as 0.1 mg/kg to 100 mg/kg per day, such as 0.01 mg/kg to 10
mg/kg per day, such as 0.01 mg/kg to 2 mg/kg per day, including 0.02 mg/kg to 2 mg/kg per day.
In other embodiments, the oral dosage may range from 0.01 to 100 mg/kg four times
per day
(QID), such as 0.01 to 50 mg/kg QID, such as 0.01 mg/kg to 10 mg/kg QID, such as 0.01 mg/kg
to 2 tug/kg QlD, such as 0.01 to 0.2 trig/kg QID. In other embodiments, the oral dosage
range from 0.01 mg/kg to 50 mg/kg three times per day (TID), such as 0.01 mg/kg to 10 mg/kg
TED, such as 0.01 mg/kg to 2 mg/kg TlD, and including as 0.01 mg/kg to 0.2 mg/kg TID. In yet
other ments, the oral dosage may range from 001 mg/kg tolOO mg/kg two times
per day
(BID), such as 0.01 mykg to 10 mg/kg BID, such as 0.01 mg/kg to 2 mg/kg BID, including 0.01
mg/kg to 0.2 mg/kg BID. The amount of compound administered will depend on the potency
and concentration of the specific NASP, the magnitude or procoagulant effect desired, the
inherent tivity of the NASP, as well as the desired enhancement of gastrointestinal
resorption.
As discussed above, compositions ning a NASP in combination with a
gastrointestinal epithelial barrier permeation enhancer as provided by s of the invention
may be orally administered in ation with other NASPs, gastrointestinal epithelial barrier
tion enhancers or other therapeutic agents, such as hemostatic agents, blood factors, or
other tions according to a dosing schedule relying on the judgment of the clinician and
needs of the subject. As such, dosing schedules may include, but is not limited to administration
five times per day, four times per day, three times per day, twice per day, once per day, three
times per week, twice per week, once per week, twice per month, once per month, and any
combination thereof.
’Jl In some embodiments, the bleeding disorder may be a chronic condition (e.g., a
congenital or acquired coagulation factor ncy) requiring the subject methods and
compositions in multiple doses over an extended period. Alternatively, methods and
compositions of the invention may be administered to treat an acute condition (e.g., bleeding
caused by surgery or trauma, or factor inhibitor/autoimmune episodes in subjects receiving
coagulation replacement therapy) in single or multiple doses for a relatively short period, for
example one to two weeks.
In practicing embodiments of the invention, one or more therapeutically effective cycles
of treatment will be administered to a subject. By peutically effective cycle of ent”
is meant a cycle of ent that when administered, brings about the d therapeutic
response with respect to treatment, For example, one or more therapeutically effective cycles of
treatment may increase the rate of blood clotting as determined by blood clotting assays (e.g.,
CAT, aPI‘T, described in detail below) by 1% or more, such as 5% or more, such as 10% or
more, such as 15% or more, such as 20% or more, such as 30% or more, such as 40% or more,
such as 50% or more, such as 75% or more, such as 90% or more, such as 95% or more,
including increasing the rate of blood clot formation by 99% or more. In other instances, one or
more therapeutically effective cycles of treatment may increase the rate of blood clot formation
by 1.5-fold or more, such as 2-fold or more, such as 5-fold or more, such as lO-fold or more,
such as 50-fold or more, including increasing the rate of blood clot formation by lOO-fold or
more. In some embodiments, subjects treated by s of the invention exhibit a positive
therapeutic response. By “positive therapeutic response" is meant that the subject exhibits an
improvement in one or more symptoms of a bleeding disorder. For example, a subject exhibiting
a positive therapeutic response to methods provided by the invention may include but is not
d to responses such as shortened blood clotting times, reduced ng, reduced need for
factor ement therapy or a combination thereof. In n embodiments, more than one
3O therapeutically effective cycle of treatment is administered.
As reviewed above, in cing methods according to certain embodiments, a
ition having a procoagulant amount of a NASP in combination with a gastrointestinal
epithelial barrier permeation enhancer is administered to a subject to enhance blood coagulation
in the subject. Any convenient mode of administration may be employed so long as the
ition is ed through the gastrointestinal epithelium. As such, modes of
administration may include oral stration or by stric tube (e.g., feeding tube or NG-
tube). As discussed in greater detail below, pharmaceutical compositions of the invention may
PCT/U52012/047248
be in the form of a liquid solution or suspension, syrup, tablet, capsule, powder, gel, or any
combination thereof. Where a ition having a procoagulant amount of a NASP and
gastrointestinal epithelial barrier permeation enhancer is orally administered in combination with
a blood coagulation factor, as discussed in detail above, the mode of administration for the NASP
and gastrointestinal epithelial barrier permeation enhancer component
may be the same or
different than for the blood ation factor. For example, in some instances, the composition
having a procoagulant amount of a NASP and gastrointestinal epithelial barrier permeation
enhancer may be administered orally, whereas the blood coagulation factor
may be locally
d (e.g., as a cream). In other instances, both the composition having a procoagulant
amount of a NASP gastrointestinal epithelial barrier permeation er and the blood
coagulation factor are administered orally.
In certain embodiments, methods of the invention provide for orally administering
composition having a procoagulant amount Of a NASP and gastrointestinal epithelial barrier
permeation enhancer prophylactically, such as for example before planned surgery. The
composition may be adtninistered prophylactically as desired, such as one hour or more prior to a
d procedure, such as 10 hours prior to a planned procedure, such as 24 hours prior to a
planned ure, and including one week prior to a planned procedure. In some instances, the
composition administered prior to or during a planned procedure may be a sustained-release
formulation (e.g., sustained release caplets or s), as bed in greater detail below.
In certain embodiments, compositions of the invention can be orally administered prior
to, concurrent with, or subsequent to other agents for treating related or unrelated conditions. If
provided at the same time as other agents, compositions of the invention can be provided in the
same or in a different ition. Thus, NASPs and gastrointestinal epithelial barrier
permeation enhancers of interest and other agents can be presented in an oral dosage form to the
individual by way of concurrent therapy. For example, concurrent therapy may be ed by
administering itions of the invention and a pharmaceutical composition having at least
one other agent, such as a hemostatic agent or ation factor (e. g. FVHI or FIX), which in
combination comprise a eutically effective dose, according to a particular oral dosing
regimen. Similarly, one or more NASPs in combination with one or more gastrointestinal
epithelial barrier tion enhancers and eutic agents can be administered in at least one
therapeutic dose. Administration of the separate pharmaceutical compositions can be performed
simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on
different days), so long as the therapeutic effect Of the combination of these substances is caused
in the subject oing therapy.
COMPOSITIONS
PCT/U820121047248
Aspects of the invention also include oral dosage compositions for enhancing blood
coagulation in a subject. In embodiments of the invention, compositions include a procoagulant
amount of a NASP in ation with a gastrointestinal epithelial barrier permeation enhancer.
Compositions also include a combination of a procoagulant amount of a NASP with a
U! gastrointestinal epithelial barrier permeation enhancer and a blood coagulation factor. As
described in detail above, gastrointestinal lial barrier permeation enhancers include
compounds that when orally administered, increase the amount of NASP that is resorbed by the
gastrointestinal system. Furthermore, intestinal permeation enhancers may also accelerate
the initiation (i.e., reducing the amount time for tion to begin) of NASP resorption through
the gastrointestinal epithelium as well as accelerate the overall rate of transport. of the NASP
across the gastrointestinal epithelium of the subject (i.e., reducing the amount of time for NASP
resorption by the gastrointestinal system to be complete).
As noted above, gastrointestinal lial barrier permeation enhancers may increase the
amount of NASP ed by the gastrointestinal system. For example, gastrointestinal epithelial
barrier permeation enhancers may increase the amount of NASP resorbed by the gastrointestinal
system by 5% or more, such as by 10% or more, such as by 25% or more, such as by 50% or
more, such as by 75% or more, such as by 90% or more, such as 95% or more, as compared to a
suitable control. In other embodiments, gastrointestinal epithelial barrier permeation enhancers
in oral compositions of the invention accelerate the initiation of NASP resorption through the
gastrointestinal epithelium. For example, gastrointenstinal epithelial barrier permeation
enhancers of the invention may reduce the amount of time required to initiate resorption of the
NASP by 5% or more, such as by 10% or more, such as by 25% or more, such as by 50% or
more, such as by 75% or more, such as by 90% or more, such as 95% or more, as compared to a
suitable control. In yet other embodiments, gastrointestinal epithelial barrier tion
enhancers in oral compositions of the invention increase the rate of resorption of the NASP. For
e, gastrointestinal epithelial barrier tion enhancers may se the rate of NASP
resorption by 2% or more, such as by 5% or more, such as by 10% or more, such as by 25% or
more, such as by 50% or more, such as by 75% or more, such as by 100% or more, such as by
200% or more, including by 500% or more, as compared to a suitable. control.
3O In n instances, gastrointestinal epithelial tion ers in oral compositions
of the invention may se the tion of NASPs as determined by Caco-2 cell models. For
e, gastrointestinal epithelial barrier permeation enhancers of the invention may increase
the resoprtion as determined by Caco-Z cell models by 2% or more, such as by 5% or more, such
as by 10% or more, such as by 25% or more, such as by 50% or more, such as by 75% or more,
such as by 100% or more, such as by 200% or more, including by 500% or more, as compared to
a suitable control.
2012/047248
As sed in detail above, oral dosage compositions of the invention include
one or more
NASPs in combination with one or more gastrointestinal epithelial barrier permeation enhancers.
Gastrointestinal lial barrier permeation enhancers in the compositions of interest
may vary. In
some embodiments, gastrointestinal epithelial barrier permeation enhancers
are tight on
modulators. For example, tight on tors in oral dosage compositions of the invention
may include, but are not limited to enzymes, bile acids, polysaccharides, fatty acids and salts f
and any combination thereof.
In some instances, tight junction modulators are polysaccharides. For example, the
polysaccharide tight junction tor, in certain instances may be chitosan. an, as discussed
above, refers to the linear copolymer of 2-acetamidedeoxy-B-D‘glucopyranose and 2-amino-l3~D-
glucopyranose made by N-deactylation of chitin. ccharide tight junction modulators may also
include, derivatives of chitosan such as N—alkyl an, acylated Chitosan, thiolated Chitosan,
phosphorylated Chitosan, chitosan cyclodextrin, N-(aminoalkyl) Chitosan, succinyl chitosan and
octanoyl chitosan, among others.
In other instances, tight junction modulators are bile acids. Suitable bile acid tight junction
modulators may include but are not limited to cholic acid (cholate), holic acid (deoxycholate),
chenodeoxycholic acid deoxycholate), ursodeoxycholic acid (ursodeoxycholate), glycocholic
acid (glycocholate), taurocholic acid (taurocholate) and lithocholic acid (lithocholate),
among others.
In other instances, tight junction modulators are
enzymes, For example, in certain
itions of the invention, the enzyme tight junction tors is a protease, such as bromelain.
In yet other instances, tight junction modulators are fatty acids and fatty acid salts thereof.
Fatty acid tight junction modulators in compositions of the invention may vary, and may include any
one or a combination of medium chain fatty acids, such as for example C8 (caprylate), C10 (caprate)
and C12 (laurate) fatty acids and fatty acid salts thereof. In certain instances, for example, the fatty
acid tight junction modulator is sodium caprate.
In certain embodiments, oral dosage compositions of the invention include two or
more
gastrointestinal epithelial barrier permeation enhancers. For example, itions may include
two or more tight junction modulators, such as three or more tight junction modulators, including
four or more tight junction modulators. Compositions may include any combination of tight
junction modulators, such as for example, a polysaccharide and a protease, a fatty acid and
polysaccharide, a polysaccharide and a bile acid, a polysaccharide, a fatty acid and a bile acid,
two different ccharides or two different bile acids, among other combinations. Where
compositions include more than one gastrointestinal epithelial barrier permeation enhancer, the
mass tage of each gastrointestinal epithelial barrier permeation enhancer may vary,
ranging from 1% or more of the total mass of the composition, such as 2% or more, such as 5%
or more, such as 10% or more, such as 25% or more and including 50% or more of the total mass
of the composition.
2012/047248
In certain instances, compositions of the invention include chitosan and bromelain.
Where the composition includes a combination of chitosan and bromelain, the mass ratio of
chitosan and ain may vary, ranging between 1:1 and 1:25; 1:2.5 and 1:5; 1:5 and 1:10;
1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and 1:150:11150 and 1:200; 1:200 and
1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range thereof. For example, the mass ratio of
chitosan to bromelain may range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and
1:100; 1:50 and 1:500; or 1:100 and 1:1000. In some embodiments, the mass ratio of bromelain
to chitosan ranges between 1:1 and 1:25; 1:2.5 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and
1:50; 1:50 and 1:100;1:100 and 1:150; 1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500;
1:500 and 1:1000, or a range thereof. For example, the mass ratio of bromelain to chitosan may
range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or
1:100 and 1:1000.
Where compositions of the invention include a combination of chitosan and ain,
the concentration of chitosan may also vary, ranging from about 0.1% to about 5%, such as about
0.15% to about 4.5%, such as 0.2% to about 4%, such as about 0.25% to about 3.5%, such as
0.3% to about 3%, such as 0.5% to about 25%, including about 0.5% to 1.5%. se, where
a combination of chitosan and bromelain are employed, in certain ments, the
concentration of bromelain may also vary, ranging from about 0.01 mg/mL to about 1.0 mg/mL,
such as about 0.2 mg/mL to about 0.9 mg/mL, such as 0.25 mg/mL to about 0.75 mg/mL, such as
about 0.3 mg/mL to about 0.6 mg/mL, ing about 0.4 mg/mL to about 0.5 mg/mL. In
certain instances, the concentration of chitosan is about 3% and the concentration of bromelain is
about 0.5 mg/mL.
As described above, NASPs in oral dosage compositions of the invention are ed
polysaccharides that demonstrate procoagulant activity. The non-anticoagulant properties of
NASPs may be determined using clotting assays, ing calibrated automated thrombography
(CAT) in Factor VIII and/or Factor 1X deficient plasma, dilute prothrombin time (dPT) or
activated l thromboplastin time (aPIT) clotting assays. One measure of noncoagulant
activity is to compare the NASP in question with the known anticoagulant heparin. For example,
NASPS may exhibit one—third or less, such as one~tenth or less of the anticoagulant activity
(measured by statistically significant increase in clotting time) of unfractionated heparin (MW
range 8,000 to 30,000; mean 18,000 Daltons). Thus, a NASP can demonstrate at least a two-fold
lower anticoagulant activity as compared to n, such as a two- to five-fold or lower
anticoagulant activity as compared to heparin, and including a two- to 10-fold or lower
anticoagulant activity as compared to heparin, using any of the various clotting assays detailed
herein.
In some embodiments, oral dosage compositions of the invention e a natural
NASP in ation with a gastrointestinal epithelial barrier permeation enhancer. As
PCT/U82012/047248
discussed above, natural NASPs may be NASPs found or derived from a lly occurring
source, such as from an animal or plant source and may encompass a broad range of subclasses
including derivatives of heparins, glycosaminoglycans, fucoidans, carrageenans, pentosan
polysulfates, dermatan sulfates and dextran es. In some embodiments, natural NASPs of
the invention are extracted from a biological source. By “biological source” is meant
a naturally-
ing organism or part of an organism. For example, NASPs of st may be extracted
from plants, animals, fungi or bacteria. In particular, NASPs of interest may be extracted from
edible seaweeds, brown algae, echinoderms (e.g., sea urchins, sea cucumbers) and the like. For
instance, the NASP can be extracted from the biological source by acid»base extraction,
enzymatic degradation, selective precipitation, filtration, among other procedures. l
NASPs such as those extracted from biological sources, ing but not limited to edible
seaweeds and brown algae are described in detail in co-pending U.S. Patent Application Serial
No. 12/449,712, filed February 25, 2010, the sure of which is herein incorporated by
reference, in its entirety.
In certain embodiments, natural NASPs of the invention include, but are not limited to
N-acetyl-heparin (NAH), N-acetyl~de-O-sulfated—heparin (NA-de-o-SH), de-N—sulfated—heparin
(De~NSH), ulfated-acetylated-he- parin (De-NSAH), periodate-oxidized heparin (POH),
chemically sulfated laminarin (CSL), chemically sulfated c acid (CSAA), chemically
sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO),
pentosan
lfate (FPS) and combinations thereof. In some ces, the NASP may be a low
lar weight fragment of a naturally occurring NASP. In other instances, natural NASPs
may also include biochemical or chemical derivatives of naturally occurring NASPS. In certain
ces, l NASPs are fucoidans. As described above, fucoidans are naturally—occurring
complex sulfated polysaccharide compounds which may be extracted from certain edible
seaweeds, brown algae and echinoderms (e.g., sea urchins, sea cucumbers). Examples of suitable
NASPs are also described in greater detail in United States Patent Application Serial No.
11/140,504, filed on May 27, 2005, now United States Patent No. 7,767,654 and in United States
Patent Application Serial No. 13/006,396 filed on January 13, 2011, the disclosures of which are
herein incorporated by reference in their entirety.
NASPs of st may range in average molecular weight from about 10 daltons to about
500,000 daltons, such as from about 100 daltons to about 0 daltons, such as from 1000 daltons
to 250,000 daltons, including 1000 daltons to 150,000 daltons. Molecular weights of NASPs can be
ined by any convenient protocol, such as for example, gel permeation chromatography or
high-performance size-exclusion chromatography (HPSEC), ary electrophoresis, PAGE
(polyacrylamide gel electrophoresis), agarose gel electrophoresis, among others.
In some embodiments, NASPs of interest may be geneous mixtures of sulfated
polysaccharides having varying molecular weights. For example, in some instances, 5% or more of
PCT/U52012/047248
the NASP composition has a molecular weight that ranges from 10 to 30,000 daltons, such as 10% or
more, such as 25% or more, such as 50% or more, such as 75% or more, such as 90% or more,
including 95% or more of the NASP composition has a molecular weight that ranges from 10 to
,000 daltons. In other embodiments, 5% or more of the NASP composition has a molecular weight
LII that ranges from 30,000 daltons to 75,000 daltons, such as 10% or more, such as 25% or more, such
as 50% or more, such as 75% or more, such as 90% or more, ing 95% or more of the NASP
composition has a molecular weight that ranges from 30,000 to 75,000 daltons. In yet other
embodiments, 5% or more of the NASP composition has a molecular weight that are greater than
75,000 daltons, such as 10% or more, such as 25% or more, such as 50% or more, such as 75% or
more, such as 90% or more, ing 95% or more of the NASP composition has a molecular
weight that is greater than 75,000 daltons.
In certain embodiments, low molecular weight NASPS may be employed for enhancing
blood ation as provided by s and compositions of the invention. By “low molecular
weight NASP” is meant a NASP having a weight average molecular weight that ranges from about
to 30,000 daltons, such as for example 100 to 30,000 daltons, such as 500 to 25,000 daltons, such
as 1000 to 15,000 daltons and including 5000 to 10,000 daltons. Examples of low molecular weight
NASPs may include, but are not limited to naturally occurring or synthetic NASPS having a
molecular weight g from 10 to 30,000 daltons, such as from 5000 to 10,000 daltons, fragments
of larger molecular weight NASPs produced by acid or enzyme hydrolysis of the larger molecular
2O weight NASP, or may be isolated fractions having molecular weights ranging from 10 to 30,000
daltons,such as 5000 to 10,000 daltons from a fractionated NASP sample.
In certain embodiments, itions of the present invention include a gastrointenstinal
epithelial barrier permeation enhancer (e.g., sodium caprate, deoxycholate, bromelain or an)
and a low molecular weight natural NASP. For instance, compositions of interest may e a
Fucus vesiculosus fucoidan having a molecular weight of 20,000 daltons or less in combination with
a gastrointenstinal epithelial barrier permeation enhancer. For e, compositions of interest may
include one or more of Fucus vesiculosus Ev. DSlOOl 108, Fucus vesiculosus F.v. SK110144B in
combination with one or more of deoxycholate, bromelain and chitosan. In r example,
compositions of interest may include one or more of FUCHS vesiculosus Ev. D8100] 108, Furns
vesiculosus F.v. SKl 10144B in combination with a mixture of chitosan and bromelain. In certain
other embodiments, itions of the present ion include a gastrointestinal epithelial barrier
permeation er (e.g., sodium caprate, deoxycholate, bromelain or chitosan) and low lar
weight synthetic NASP. For instance, certain compositions may include one or more of a sulfated 6-
carboxyicodextrin, a ed B-cyclodextrin and a sulfated maltopentose having a molecular weight
of 25,000 daltons or less in combination with a gastrointestinal epithelial r permeation
enhancer. For example, compositions of interest may include one or more of a 24,000 dalton sulfated
WO 12954
6-carboxyicodextrin, a 14,000 dalton sulfated 6-carboxyicodextrin, a sulfated B-cyclodextrin and a
sulfated maltopentose in combination with one or more of deoxycholate, bromelain and chitosan. In
another example, itions of interest may include one or more of a 24,000 dalton sulfated 6—
carboxyicodextrin, a 14,000 dalton sulfated 6-carboxyicodextrin, a sulfated B-cyclodextrin and a
sulfated maltopentose in combination with a mixture of chitosan and bromelain.
In some embodiments, NASPs are ted from a biological source and
may be
fractionated to isolate low molecular weight NASPs (i.e., fractions containing NASPs having
molecular weight ranging from lO-30,000 daltons). Any convenient protocol may be used to
fractionate NASPs of interest, including but not limited to size exclusion chromotagraphy, gel
tion chromotagraphy, capillary electrophoresis, among others.
In certain instances, low molecular weight NASPs obtained by fractionating a NASP sample
may be employed for ing blood coagulation as provided by the methods and compositions of
the invention. For example, NASPs extracted from a biological source
may be fractionated to isolate
NASPs having molecular weights that range from 10 to 30,000 daltons, such as 10 to 5000 daltons,
such as 5000 to 10,000 daltons, such as 10,000 to 15,000 daltons, and including 15,000 to 30,000
daltons. In certain embodiments, one or more of these fractions may be orally administered in
combination with a gastrointestinal epithelial barrier permeation enhancer for enhancing blood
coagulation in a subject, such as by the methods described above.
In certain embodiments, different molecular weight ons may be prepared by acid-
hydrolysis or radical depolymerization of high molecular weight NASP. The molecular weight
ranges of the resulting products may be adjusted based upon the stringency of the hydrolysis or
depolymerization conditions employed. ons may then be further purified using ion exchange
chromatography. For instance, to obtain middle and low molecular weight fractions of NASP, high
molecular weight NASP may be hydrolyzed using an acid such as HCl (or
any other suitable acid) at
concentrations ranging from 0.02 to 1.5 M and at temperatures g from 25°C to 80°C.
Hydrolysis on times will typically range from 15 minutes to several hours. The resulting
hydrolyzed on mixture is then neutralized by on of base (e.g., sodium hydroxide). Salts
are subsequently removed, for example, by electrodialysis, and the hydrolysis products are analyzed
to ine weight average molecular weight, saccharide content, and sulfur content, using
conventional analytical techniques for carbohydrate is. Alternatively, enzymatic s may
be employed to degrade NASPs using, e.g., glycosidases. NASPs for use in the invention
may be
heterogeneous or homogeneous, depending upon the degree of separation employed.
In certain ments, oral dosage compositions of the ion include a blood
coagulation factor in ation with a gastrointestinal lial barrier permeation enhancer and a
fucoidan, such as for example, Fucoidan 5307002, Fucus vesiculosus, max. MW peak 126.7 kD;
Fucoidan VG49, Fucu: vesiculosus, hydrolyzed sample of 5307002 of lower MW, max. MW peak
PCT/U320121047248
22.5 kD; Fucoidan VG57, Undaria pinnarifida, high charge (high sulfation, deacetylated); Fucoidan
GFS (5508005), Undarz‘a pinnatifida, depyrogenated; Fucoidan GFS (L/FVF-01091), Fucus
vesiculosus, depyrogenated, max. MW peak 125 kD; Fucoidan GFS (L/FVF—O1092), Fucus
vesiculosus, depyrogenated, max. MW peak 260 kD; Fucoidan GFS (L/FVF-01093), Fucus
UI vesiculosus, yzed depyrogenated, max. MW peak 36 kD; Maritech® ia a extract;
Maritech® Ecklom‘a maxima extract; Maritech® ystis pyrifera extract; Maritech® Immune
trial Fucoidan Blend; and any combinations thereof,
In other embodiments, oral dosage compositions of the invention may include a synthetic
NASP in combination with a gastrointestinal epithelial barrier permeation enhancer. Synthetic
NASPs are ed polysaccharides which are partially or wholly produced by man—made
methods (e.g., chemical synthesis). For example, the synthetic NASP may be a sulfated
oligomer, such as a sulfated oligosaccharide or a sulfated aliphatic. In certain ces,
tic NASPs are ed pentoses, sulfated hexoses or sulfated cyclodextrins. For example,
synthetic NASPs may include, but are not limited to sulfated maltopentoses, sulfated betacyclodextrins
, sulfated 6-Carboxyicodextrin and derivatives f.
Oral dosage compositions of the ion may include one or more NASPs, as desired.
For example, two or more NASPS may be combined, such as three or more NASPs and including
four or more NASPs. Where more than one NASP is combined together, all of the NASPs may
be natural NASPs, all of the NASPS may be synthetic NASPS or any combination f.
Where oral compositions e more than one NASP, the mass percentage of each NASP in the
composition may vary, g from 1% or more of the total mass of the composition, such as
2% or more, such as 5% or more, such as 10% or more, such as 25% or more and including as
50% or more of the total mass of the composition.
In embodiments of the invention, the mass ratio of the one or more NASPs and the one
or more gastrointestinal epithelial barrier permeation enhancers in the oral dosage compositions
may vary, ranging between 1:1 and 1:25; 1:2.5 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and
1:50; 1:50 and 1:100; 1:100 and 1:150; 1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500;
1:500 and 1:1000, or a range thereof. For example, the mass ratio of the NASP to the
gastrointestinal epithelial barrier permeation enhancer may range between 1:1 and 1:10; 1:5 and
1:25; 1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000. In some
embodiments, the mass ratio of the gastrointestinal epithelial barrier permeation enhancer to the
NASP ranges between 1:1 and 1:25; 1:2.5 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and 1:50;
1:50 and 1:100; 1:100 and 1:150; 1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and
1:1000, or a range thereof. For example, the mass ratio of the gastrointestinal epithelial barrier
permeation enhancer to the NASP may range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50;
1:25 and 1:100; 1:50 and 1:500; or 1:100 and 1:1000.
-38—
In addition, oral dosage compositions of the invention may also include one or more
blood coagulation factors. For example, compositions may include an amount of one or more
NASPS and one or more gastrointestinal epithelial barrier permeation enhancers in combination
with one or more blood coagulation factors. Blood coagulation s of interestinclude, but are
LII not limited to factor XI, factor XII, prekallikrein, high molecular weight kininogen (HMWK),
factor V, factor VII, factor VIII, factor IX, factor X, factor XIII, factor II, factor VIIa, and von
Willebrands , factor Xa, factor IXa, factor XIa, factor XIIa, and VIIIa, prekallekrein, and
high-molecular weight kininogen, tissue factor, factor VIIa, factor Va, and factor Xa.
The amount (i.e., mass) of each of the NASP, the gastrointestinal epithelial barrier
'10 permeation enhancer and blood coagulation factor in oral dosage compositions of interest may vary,
ranging from 0.001 mg to 1000 mg, such as 001 mg to 500 mg , such as 0.1 mg to 250 mg, such as
0.5 mg to 100 mg, such as 1 mg to 50 mg, including 1 mg to 10 mg. As such, in the subject
compositions, the mass ratio of the NASP and gastrointestinal epithelial barrier permeation enhancer
to blood coagulation factor may vary, and in some instances may range between 1:1 and 1:25; 1:25
and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and :50 and 1:100; 1:100 and 1:150; 1:150 and
1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range thereof. For example, the
mass ratio of the NASP and gastrointestinal epithelial barrier permeation enhancer to blood
coagulation factor may range between 1:1 and 1:10; 1:5 and 1:25; 1:10 and 1:50; 1:25 and 1:100;
1:50 and 1:500; or 1:100 and 1:1000. In some embodiments, the mass ratio of the blood coagulation
factor to the NASP and gastrointestinal epitheliaI barrier permeation enhancer ranges n 1:1
and 1:25; 1:25 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:100; 1:100 and
1:150; 1:150 and 1:200; 1:200 and 1:250; 1:250 and 1:500; 1:500 and 1:1000, or a range thereof. For
example, the mass ratio of the blood coagulation factor to the composition that contains a NASP and
gastrointestinal epithelial barrier permeation enhancer may range between 1:1 and 1:10; 1:5 and 1:25;
1:10 and 1:50; 1:25 and 1:100; 1:50 and 1:500; or 1:100 and 111000.
Oral dosage compositions may be homogeneous, containing only a single type of NASP and
single type of gastrointestinal lial permeation barrier enhancer. In other ments,
itions of interest are heterogenous mixtures of two or more NASPs or two or more
gastrointestinal lial permeation barrier enhancers. For example, heterogenous mixtures may
3O n two or more NASPs and two or more gastrointestinal epithelial permeation barrier ers.
In other instances, heterogeneous es may contain one NASP and two or more gastrointestinal
epithelial permeation barrier enhancers. In yet other instances, heterogeneous mixutres may contain
two or more NASPs and one gastrointestinal epithelial permeation barrier enhancer,
In certain embodiments, oraI dosage compositions of the invention may further include
one or more pharmaceuticaliy acceptable excipients or oral dosage delivery vehicle as part of a
pharmaceutical ition. Excipients may include, but are not d to, carbohydrates,
inorganic salts, antimicrobial agents, antioxidants, surfactants, water, alcohols, polyols,
PCT/U820121047248
glycerine, vegetable oils, phospholipids, buffers, acids, bases, and any ations thereof. A
carbohydrate such as a sugar, 21 derivatized sugar such as an alditol, aldonic acid, an fied
sugar, and/or a sugar polymer may also be employed. Some carbohydrate excipients of st
include, for example, monosaccharides, such as fructose, maltose, galactose, glucose, D-
U! mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and
the like; polysaccharides, such as raftinose, melezitose, maltodextrins, dextrans, starches, and the
like; and alditols, such as mannitol, xylitol, maltitol, lactitol, l, sorbitol (glucitol), pyranosyl
sorbitol, myoinositol, and the like. Inorganic salts may include, but are not limited to citric acid,
sodium chloride, potassium chloride, sodium e, potassium nitrate, sodium ate
monobasic, sodium phosphate dibasic, and any combinations thereof.
In certain embodiments, oral dosage compositions of the invention may also include an
antimicrobial agent for preventing or deterring microbial growth, such as for example
konium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride,
chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimersol, and any
combinations thereof.
One or more antioxidants may also be employed. Antioxidants, which can reduce or
prevent oxidation and thus deterioration of the composition, may include, for example, ascorbyl
ate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid,
monothioglycerol, propyl gallate, sodium bisulfite, sodium dehyde sulfoxylate, sodium
metabisulfite, and any combinations thereof.
One or more surfactants may also be included in compositions of the invention. For
example, suitable surfactants may include, but are not limited to polysorbates, such as "Tween
" and "Tween 80," and pluronics such as F68 and F88 (BASF, Mount Olive, New Jersey);
sorbitan esters; lipids, such as olipids such as lecithin and other phosphatidylcholines,
phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty
esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other s.
Acids or bases may also be present in oral dosage compositions of the invention. For
example, acids may include but are not limited to hydrochloric acid, acetic acid, phosphoric acid,
citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid,
phosphoric acid, sulfuric acid, fumaric acid, and any combinations thereof. Examples bases
include, but are not limited to sodium hydroxide, sodium acetate, ammonium hydroxide,
potassium ide, ammonium acetate, potassium acetate, sodium phosphate, ium
phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium
te, and any combinations f.
The amount of any individual excipient in the oral dosage composition will vary
ing on the nature and function of the excipient, oral dosage delivery vehicle and particular
needs of the composition. Typically, the l amount of any individual excipient is
PCT/U32012/047248
determined through routine experimentation, i.e., by preparing compositions containing varying
amounts of the excipient (ranging from low to high), examining the stability and other
parameters, and then determining the range at which optimal performance is attained with no
significant e effects. Generally, however, the excipient(s) will be present in the oral
dosage composition in an amount of about 1% to about 99% by weight, such as from about 5% to
about 98% by weight, such as from about 15 to about 95% by weight of the excipient, including
less than 30% by weight. Pharmaceutical excipients along with other excipients that
may be
employed in compositions of interest are described in "Remington: The Science & Practice of
Pharmacy", 19th ed., Williams & Williams, (1995), the "Physician’s Desk nce", 52nd ed.,
Medical Economics, Montvale, NJ (1998), and Kibbe, A.H., Handbook of ceutical
Excipients, 3rd Edition, American Pharmaceutical Association, Washington, D.C., 2000, the
sure of which is herein incorporated by reference.
As described above, compositions of the ion may be stered by
convenient mode of administration so long as the ition is resorbed through the
gastrointestinal epithelium (e.g., orally or by nasogastric tube). As such, the formulation may
vary. For example, compositions of the invention may be powders or lates that
can be
reconstituted with a solvent prior to use, dry insoluble compositions for combination with
vehicle prior to use, and emulsions and liquid concentrates for dilution prior to administration.
Diluents for reconstituting solid compositions may include, but are not limited to bacteriostatic
water for injection, dextrose 5% in water, phosphate buffered saline, ’s solution, saline,
sterile water, deionized water, and any combinations thereof. In some embodiments,
pharmaceutical compositions of the invention may be in the form of a liquid solution or
suspension, syrup, tablet, capsule, powder, gel, or any combination thereof for ingestion or
ation by a nasogastric tube. For e, oral dosage compositions of the invention
be pre-loaded into a tablet, a e, caplet device, or the like, depending
upon the intended use.
In certain embodiments, the compositions are in unit dosage form, such that an amount of the
composition is ready in a single oral dose, in a premeasured or pre-packaged form.
UTILITY
The t methods and compositions find use in any situation where there is a desire to
e blood coagulation in a subject, a desire to enhance resorption of NASPs through the
gastrointestinal system and the subject is responsive to treatment with a NASP and a
gastrointestinal epithelial barrier permeation enhancer. In certain ments, the subject
methods and compositions may be employed to treat bleeding disorders, such as a chronic or
acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, an
acquired coagulation disorder and stration of an agulant. For example, bleeding
PCTIU52012/047248
disorders may include, but are not limited to hemophilia A, hemophilia B, von Willebrand
disease, idiopathic thrombocytopenia, a deficiency of one or more contact factors, such as Factor
XI, Factor XII, prekallikrein, and high lar weight kininogen (HMWK), a deficiency of
one or more factors associated with clinically significant bleeding, such as Factor V, Factor VII,
U! Factor VIII, Factor IX, Factor X, Factor XIII, Factor II rothrombinemia), and von
Willebrands factor, a vitamin K deficiency, a er of fibrinogen, including afibrinogenemia,
hypofibrinogenemia, and dysfibrinogenemia, an alphaz—antiplasmin deficiency, and excessive
bleeding such as caused by liver e, renal disease, thrombocytopenia, platelet dysfunction,
hematomas, internal hemorrhage, hemarthroses, y, trauma, hypothermia, menstruation, and
ncy.
The subject methods and compositions also find use in enhancing blood coagulation to
treat a congenital coagulation er or an acquired coagulation disorder caused by a blood
factor deficiency. The blood factor deficiency may be caused by deficiencies of one or more
factors, including but not limited to, factor V, factor VII, factor VIII, factor IX, factor XI, factor
XII, factor XIII, and von Willebrand .
The subject methods and compositions also find use in enhancing blood coagulation in
order to improve hemostasis in treating bleeding disorders, such as those associated with
deficiencies of coagulation factors or for reversing the effects of anticoagulants in a subject. For
e, enhancing blood coagulation by methods and compositions of the invention may be
employed to treat bleeding ers such as congenital coagulation disorders, acquired
coagulation disorders, and hemorrhagic conditions induced by trauma. Examples of bleeding
disorders that may be treated with NASPs and gastrointestinal epithelial barrier permeation
enhancers include, but are not limited to, hemophilia A, hemophilia B, von rand disease,
thic thrombocytopenia, a deficiency of one or more contact factors, such as Factor XI,
Factor XII, prekallikrein, and high molecular weight kininogen (HMWK), a deficiency of one or
more factors associated with clinically significant bleeding, such as Factor V, Factor VII, Factor
VIII, Factor IX, Factor X, Factor XIII, Factor II (hypoprothrombinemia), and von Willebrands
factor, a vitamin K ency, a er of fibrinogen, including nogenemia,
hypofibrinogenemia, and dysfibrinogenenna, an alphayantiplasmin deficiency, and excessive
3O bleeding such as caused by liver disease, renal disease, thrombocytopenia, et dysfunction,
hematomas, internal hemorrhage, hemarthroses, surgery, trauma, hypothermia, menstruation, and
pregnancy. In certain embodiments, methods and compositions of the ion are used to treat
congenital coagulation ers including hemophilia 1A, hemophilia B, and von Willebrands
disease. In other embodiments, NASPs are used to treat acquired coagulation disorders,
including deficiencies of factor VIII, von Willebrand factor, factor IX, factor V, factor XI, factor
X11 and factor XIII, particularly disorders caused by inhibitors or munity against blood
PCT/U82012/047248
coagulation factors, or haemostatic disorders caused by a disease or ion that results in
reduced synthesis of coagulation factors.
In some ments, the bleeding disorder may be a c ion (e.g., a
congenital or acquired coagulation factor deficiency) requiring the subject methods and
compositions in multiple doses over an extended . Alternatively, methods and
compositions of the ion may be orally administered to treat an acute condition (e. g.,
bleeding caused by surgery or trauma, or factor inhibitor/autoimmune episodes in ts
receiving coagulation ement therapy) in single or multiple doses for a relatively short
period, for example one to two weeks.
IO The subject methods and compositions also find use in enhancing blood coagulation in a
subject undergoing a surgical or invasive procedure.
The subject methods and compositions also find use in enhancing blood coagulation in
order to e the s of an anticoagulant in a subject, the method comprising stering
a eutically effective amount of a composition comprising a procoagulant amount of a
NASP in combination with a gastrointestinal epithelial barrier permeation enhancer to the
subject. In certain embodiments, the subject may have been treated with an anticoagulant
including, but not limited to, heparin, a coumarin derivative, such as warfarin or dicumarol,
TF'PI, AT III, lupus anticoagulant, de anticoagulant peptide (NAPCZ), active-site blocked
factor VIIa (factor Vflai), factor IXa inhibitors, factor Xa inhibitors, including fondaparinux,
idraparinux, DX-9065a, and razaxaban (DPC906), inhibitors of factors Va and VIIIa, including
activated protein C (APC) and soluble thrombomodulin, thrombin inhibitors, including hirudin,
bivalirudin, argatroban, and ximelagatran. In certain embodiments, the anticoagulant in the
subject may be an antibody that binds a clotting factor, including but not limited to, an antibody
that binds to Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor II, Factor
XI, Factor XII, von Willebrands factor, prekallikrein, or high molecular weight kininogen
(HMWK).
In another aspect, the invention provides a method for treating a subject undergoing a
surgical or ve procedure wherein ed blood clotting would be desirable, comprising
orally administering a therapeutically effective amount of a composition comprising a
3O procoagulant amount of a NASP in combination with a gastrointestinal epithelial barrier
permeation enhancer as detailed herein to the subject. In certain embodiments, the NASP and
gastrointestinal epithelial barrier permeation er can be coadministered with one or more
different NASPs and one or more different gastrointestinal epithelial r permeation
enhancers, and/or in combination with one or more other therapeutic agents to the subject
oing a surgical or invasive procedure. For example, the subject may be administered a
therapeutically effective amount of one or more s selected from the group consisting of
factor XI, factor XII, prekallikrein, high molecular weight kininogen (HMWK), factor V, factor
PCT/U82012l047248
VII, factor VIII, factor IX, factor X, factor XIII, factor II, factor VIIa, and von Willebrands
factor. Treatment may further comprise administering a procoagulant, such as an activator of the
intrinsic coagulation pathway, including factor Xa, factor IXa, factor XIa, factor XIIa, and VIIIa,
prekallekrein, and high-molecular weight kininogen; or an activator of the extrinsic coagulation
UI pathway, including tissue factor, factor VIIa, factor Va1 and factor Xa. Therapeutic agents used
to treat a subject undergoing a surgical or invasive procedure can be administered in the same or
different compositions and concurrently, , or after administration of the NASP and the
gastrointestinal epithelial barrier permeation enhancer.
As disclosed above, hemostatic agents, blood factors, and medications may also be
employed. For e, the subject may be administered one or more blood ation s
such as factor XI, factor XII, prekallikrein, high molecular weight kininogen (HMWK), factor V,
factor VII, factor VIII, factor IX, factor X, factor XIII, factor II, factor VIIa, von Willebrands
factor, factor Xa, factor IXa, factor XIa, factor XIIa, and VIIIa, prekallekrein, and high~
molecular weight kininogen, tissue factor, factor VIIa, factor Va, and factor Xa.
1(rrs
Also provided are kits for use in practicing the subject methods, where the kits may
include one or more of the above compositions, e.g., an NASP composition, a gastrointestinal
epithelial r permeation enhancer composition and/or blood coagulation factor, as bed
above. The kit may further include other components, e.g., administration devices, fluid sources,
etc., which may find use in practicing the subject methods. Various ents may be
packaged as desired, e.g., together or tely.
In addition to above mentioned ents, the subject kits may further include
instructions for using the components of the kit to practice the subject methods. The instructions
for practicing the subject methods are generally ed on a suitable recording medium. For
example, the instructions may be printed, such as on paper or plastic, etc. As such, the
instructions may be present in the kits as a e , in the labeling of the container of the
kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other
embodiments, the instructions are present as an electronic storage data file present on a suitable
3O computer readable storage medium, e.g. CD~ROM, diskette, etc. In yet other embodiments, the
actual instructions are not present in the kit, but means for obtaining the instructions from a
remote , e.g. via the internet, are provided. An example of this embodiment is a kit that
includes a web address where the instructions can be viewed and/or from which the ctions
can be aded. As with the instructions, this means for obtaining the instructions is recorded
on a suitable substrate.
WO 12954 PCT/'US2012/047248
EXPERIMENTAL
The ing es are offered for illustrative purposes only, and are not intended to
limit the scope of the present invention in any way.
Efforts have been made to ensure accuracy with respect to numbers used (e. g., amounts,
temperatures, etc), but some mental error and deviation should, of course, be d for.
Bioavailability and Resorgtion Studies of NASPs in combination with Gastrointestinal
Epithelial Barrier Permeation Enhancers
The bioavailability of NASPs in combination with gastrointestinal epithelial r
permeation enhancers of st were studied using the CaCo-2 cell model screening. This
method utilizes a human colon carcinoma cell line that expresses a wide range of transporter
proteins on its cell membranes. Cell layers are grown on a membrane surface that separates two
compartments (24-well plate). An example of the experimental setup for these experiments is
illustrated in Figure 1. Selected NASP and gastrointestinal epithelial barrier permeation
enhancer samples were dissolved in RPMI cell medium at a concentration of 1 mg/mL and
applied onto the cells in the apical compartment. Cells were incubated at 37 °C in 5 % C02.
Medium samples were removed from the basolateral and apical tment at different time
points. The condition of the cell layer was monitored by measurement of the transepithelial
electrical resistance . Samples were analyzed by thrombin generation assay (CAT).
NASP concentration was calculated based on activity from CAT assay. Experimental details of
thrombin generation assays and other blood coagulation assays are described in United States
Patent ation Serial No. 11/140,504, filed on May 27, 2005, now United States Patent No.
7,767,654, and United States Patent Application Serial No. 13/006,396, filed on January13,
201 1, the disclosures of which is herein incorporated by reference.
All NASP and gastrointestinal epithelial barrier permeation enhancer samples were
d in such a way that the sample concentration was in the range of increasing procoagulant
activity. Based on the initial load concentration values, apical and basolateral concentrations
were determined at 2 hour increments (e.g., 2 hours, 4 hours, 6 hours, 8 hours, including 24
hours). Based on the determined basolateral concentrations, the t resorption was
determined for each combination of compounds (i.e., NASP and gastrointestinal lial barrier
permeation ers).
An example of the resorption s described herein is illustrated in Tables 1-3 which
summarize the apical and basolateral concentrations of the NASP, Fucoidan F.v. 1091 in
combination with the gastrointestinal epithelial barrier permeation enhancer, Bronielain (0.5
mg/mL) in the Caco-2 cell model. Table 1 illustrates that the starting apical concentration of RV.
PCTx’U$2012/047248
91 in combination with Bromelain is about 840 ug/mL. After about 8 hours, the apical
concentration of RV. L/FVF 1091 is reduced by about 25% to an average of about 627 ug/mL.
Table 1:
Sample Start (mg/mL) 8 hours (mg/mL)
Ev. LflWF 1091 —Set 1 670
F.v. L/FVF1091— Set 2 840
F.v. L/FVF1091— Set 3
Table 2 illustrates the basolateral concentrations of RV. L/FVF 1091 in combination with
ain at various time points. Figure 2 shows the basolateral concentrations of RV. L/FVF
1091 in the presence of ain (0.5 nag/ml.) in the Caco-2 system. Figure 3 shows Lhe
condition of the cell layer as measured by the corresponding transepithelial electrical resistance
curves of each trial.
Table 2:
Sample Concentration
(us/mm
Ev. L/FVF 1091 —Set 1 5.3 14.5 292
Ev. L/FVF1091— Set 2 05 2.1 6.5
F.v.L/FVF1091—- Set 3
Theoretical Maximum
Table 3 illustrates the percent (%) resorption of RV. L/FVF 1091 in the presence of
Bromelain at various time .
Table 3:
Percent Resorption “T753135 4 hours 6 hours 8 hours _'
Dilution Factor I 0.74
F.v. L/FVF 1091 —Set 1 20.7
F.v. L/FVF1091— Set 2 4.6
Ev. L/FVF 1091 — Set 3
Based on Tables 2 and 3, the average resorption is 19 mg/mL of RV. L/FVF 1091 in
combination with Bromelain at 8 hours and trate that the basolateral concentration of RV.
UFVF 1091 increases with time in the presence of the gastrointestinal epithelial r
permeation enhancer, ain.
Table 4 is a summary of percent resorption ofnatural NASPs in the Caco-2 cell model in
the presence of several gastrointestinal epithelial permeation enhancers at various
concentrations. As shown in Table 4, all of the natural NASPs demonstrated increased
resorption in the presence of the gastronintestinal epithelial barrier tion ers of
interest.
Table 4:
Average Percent U.p.5508005 F.v. L/FVF F.v. F.v.
Resorption at 8 hours 1091 DS1001108 SK110144B
Molecular Weight 380 kD 143 kD 18 kD 12 kl)
No enhancer 0.1 0.7 0.4 4.0
Sodium Caprate
. n/a
12 mM
Deoxycholate - 0.06% . 10.7
Deoxycholate - 0.08% 4.7 10.9 10.4 22.6
Bromelain - 0.5 mg/mL 6.2 8.6 28.9
Chitosan - 3% 2.5 2.5 1.6 9.0
Bromelain/Chitosan 19.6 36.9 _1
28.8 55.0
0.5 mg/mL:3%
__‘-
BromelainiChitosan n/a 3.1 6.7 n/a
0.05 mg/mL:3%
Bromelain/Chitosan n/a 4.4 7.3 n/a
0.25 mg/mL:1.5%
Bromelain/Chitosan n/a 2.6 8.7 n/a
0.5 L:O.3 %
Table 5 is a y of percent resorption of synthetic NASPs in the Caco~2 cell model
in the presence of several gastrointestinal epithelial permeation enhancers at various
concentrations. As shown in Table 5, all of the synthetic NASPs demonstrated increased
resorption in the presence of the gastronintestinal epithelial barrier permeation enhancers of
interest.
Table 5:
2012/047248
Average Percent Sulfated 6— Sulfated 6- ed {3- Sulfated
Resorptiou at 8 hours Carboxyicodextrin Carboxyicodextrin extrin Maltopentose
Molecular Weight 24kD 14kD
No enhancer
Sodium Caprate
12 mM
Deoxycholate - 0.06%
Deoxycholate - 0.08%
Bromelain ~ 0.5
mg/mL
Chitosan - 3%
Bromelain/Chitosan
0.5 3%
Figures 4-8 illustrate resorption of some natural NASPs of interest in Caco-2 cell models
as determined by TGA and liquid chromatography/mass spectrometry in combination with
different gastrointestinal epithelial barrier permeation enhancers. Figures 9 and 10 illustrate
resorption of some synthetic NASPS of interest in Caco-Z cell models as determined by TGA and
liquid chromatography/mass spectrometry in combination with different gastrointestinal
epithelial barrier permeation enhancers.
Figures 4a—b illustrate the NASP, BAXS 13 resorption in Caco—Z cell models in the
absence of any gastrointestinal epithelial barrier permeation enhancer as well as in the ce
of bromelain, chitosan and in the presence of a combination of bromelain and chitosan. As
rated in Figures 4a—b, basolateral concentrations of BAX513 are increased in the presence of
the gastrointestinal epithelial barrier tion enhancer, indicating that resorption of BAXS 13
increases when administered in combination with a gastrointestinal epithelial barrier permeation
enhancer.
Figures Sa-c rate the NASP, Fucoidan F.v. L/FVF 1091 resorption in Caco-2 cell
models in the absence of any gastrointestinal epithelial barrier permeation enhancer as well as in
the presence of several ent gastrointestinal epithelial r permeation enhancers sodium
caprate, deoxycholate, bromelain, chitosan and in the presence of a combination of bromelain
and chitosan. s Sa—c demonstrates that the basolateral concentrations of Fucoidan Fiv.
L/FVF 1091 increased in the presence of the gastrointestinal epithelial barrier permeation
enhancer, indicating that resorption of an F.v. L/FVF 1091 increases when administered in
combination with a gastrointestinal epithelial barrier permeation er. In particular, the
tion of Fucoidan F.v. L/FVF 1091 increases substantially when administered in the
WO 12954 PCT/U82012/047248
ce of a combination of chitosan and bromelain.
Figures 6a—b show the NASP, an U.p. 5 resorption in Caco-2 cell models
in the absence of any gastrointestinal epithelial barrier permeation enhancer
as well as in the
presence of gastrointestinal epithelial r permeation enhancers sodium caprate,
deoxycholate, bromelain, chitosan and in the presence of a combination of ain and
chitosan. Figures 6a—b demonstrates that the basolateral concentrations of Fucoidan U.p.
5508005 increased in the presence of a gastrointestinal epithelial barrier permeation enhancer,
indicating that resorption of Fucoidan U.p. 5508005 increases when administered in
combination with a gastrointestinal epithelial barrier tion enhancer. In particular, the
resorption of Fucoidan Up. 5508005 increased substantially in the presence of sodium caprate,
bromelain and in the ce of a combination of chitosan and bromelain.
Figures 7a-b depict the NASP, Fucoidan FvF DSIOOllOSB resorption in Caco-2 cell
models in the absence of any gastrointestinal epithelial barrier permeation enhancer
as well as in
the ce of gastrointestinal lial barrier permeation enhancers deoxycholate (at
different concentrations), bromelain, chitosan and in the
presence of a combination of bromelain
and chitosan. Figures 7a-b illustrates that the basolateral concentrations of Fucoidan FvF
DSlOOl 108B increased in the presence of a gastrointestinal epithelial barrier permeation
enhancer, indicating that resorption of an FVF DS 1001 108B increases when administered
in combination with a gastrointestinal epithelial barrier permeation enhancer. In particular, the
resorption of an FVF DSlOOl 108B increases substantially when administered in the
presence of a combination of chitosan and bromelain.
Figures 8a-b show the NASP, Fucoidan FVF SKI lOl44B resorption in Caco-2 cell
models in the absence of any gastrointestinal epithelial barrier permeation er
as well as in
the presence of gastrointestinal epithelial barrier permeation enhancers deoxycholate (at
different concentrations), bromelain, chitosan and in the
presence of a combination of bromelain
and chitosan. Figures 8a-b demonstrates that the teral concentrations of Fucoidan FVF
SKIlOl44B increased in the presence of a gastrointestinal epithelial barrier permeation
enhancer, indicating that resorption of Fucoidan FvF SKI 101448 increases when administered in
combination with a gastrointestinal lial barrier tion enhancer. In ular, the
3O resorption of Fucoidan FVF 8K110144B increased substantially in the presence of 0.08%
deoxycholate, bromelain, and in the presence of a combination of an and bromelain.
Figures 9 and 14 show the synthetic NASP, sulfated B-cyclodextrin resorption in Caco-Z
cell models in the absence of any gastrointestinal epithelial barrier permeation enhancer as well
as in the presence of gastrointestinal epithelial barrier permeation enhancers deoxycholate,
bromelain and sodium caprate. Figure 9 demonstrates that the basolateral concentrations of
sulfated B-cyclodexttin increased in the presence of a intestinal epithelial ban‘ier
S2012/047248
permeation enhancer, indicating that tion of sulfated B-cyclodextrin ses when
administered in combination with a gastrointestinal epithelial barrier permeation enhancer. In
particular, the resorption of sulfated B—cyclodextrin increased substantially in the presence of all
three of holate, bromelain, and sodium caprate at 8 hours.
Figures 10 and 15 show the tic NASP, sulfated maltopentaose resorption in Caco-
2 cell models in the absence of any gastrointestinal epithelial barrier permeation enhancer as well
as in the ce of gastrointestinal epithelial barrier permeation ers deoxycholate,
bromelain, chitosan and sodium caprate. Figure 10 trates that the basolateral
concentrations of sulfated maltopentaose increased in the presence of a gastrointestinal epithelial
barrier permeation enhancer, indicating that resorption of sulfated maltopentaose increases when
administered in combination with a gastrointestinal epithelial barrier permeation enhancer. In
particular, the resorption of sulfated maltopentaose increased substantially in the presence of
deoxycholate and bromelain at 8 hours. Sulfated maltopentaose also showed strong increased
resorption in the presence of chitosan and sodium caprate.
As demonstrated in Figures 4-10, the basolateral concentrations of both l and
synthetic NASPs are increased in the presence of each of the gastrointestinal epithelial barrier
permeation enhancers, indicating that resorption of the NASP increases when administered in
combination with a gastrointestinal lial barrier tion enhancer as compared to
resorption in the absence of gastrointestinal epithelial barrier permeation enhancer.
Figures lla-b illustrates the effect of different concentrations of chitosan and bromelain
when a combination of an and ain is employed in combination with NASPs
Fucoidan F.v. L/FVF 1091 (Figure 11a) and Fucoidan FVF DSlOOl 1088 (Figure 11b). In
particular, combinations of chitosan and brornelain include 0.3% chitosan and 0.5 mg/ml
bromelain; 1.5% chitosan and 0.25 mg/mL bromelain; 3% chitosan and 0.05 mg/mL bromalein;
and 3% an and 0.5 mg/mL bromelain. As illustrated in Figures lOa-b, a combination of 3%
chitosan and 0.5 mg/mL bromelain demonstrated the strongest tion of the NASP.
Table 6 is a summary of percent resorption of natural and synthetic NASPs in the Caco—2
cell model. As shown in Table 4, all of the NASPs demonstrated increased resorption in the
presence of the gastronintestinal epithelial barrier tion enhancers of interest.
Table 6
Avg. BAX513 F.v.L/FVF Up. 5508005 ‘F.V.D81001108B Sulfated
tion at 1091 Maltopentaose
8 hours cyclodextrin
180w— 380w
PCT/U82012/047248
No enhancer 0.3 0.6
Sodium
Caprate
(12 mM)
Deoxycholate 67.4
(0.06%)
Deoxycholate
(0.08%)
Bromelain 48.6
(0.5 mg/mL)
Chitosan
(3%)
Bromelajn
(0.5 mg/mL)
and Chitosan
(3%)
Figures lZa-b and 13a-c shows the ion of the cell layer as measured by
transepithelial electrical resistance in the ce and absence of a gastrointestinal epithelial
barrier permeation enhancers when tested with sulfated B-cyclodextrin and sulfated
(ll maltopentose, respectively. As depicted in Figures lZa—b, in the ce of sulfated B-
cyclodextrin, gastrointestinal epithelial r permeation enhancer bromelain reduce the
transepithelial electrical resistance values substantially (<300 ohms/cmz). The transepithelial
electrical resistance values remained low after on of fresh medium. Treatment with the
gastrointestinal epithelial barrier permeation er alone however, resulted in the recovery of
the transepithelial electrical resistance. Likewise, as depicted in s l3a-c, in the ce
of sulfated maltopentose, gastrointestinal epithelial barrier permeation enhancers bromelain,
deoxycholate and chitosan reduce the transepithelial electrical resistance values substantially.
r, in contrast to studies as ed in Figures lZa-b for sulfated B—cyclodextrin, the
transepithelial electrical resistance increased after removal of the gastrointestinal epithelial
barrier permeation enhancer and the maltopentaose.
PCT/U52012/047248
Although the foregoing ion has been described in some detail by way of
illustration and example for purposes of clarity of understanding, it is readily apparent to those of
ordinary skill in the art in light of the teachings of this ion that certain changes and
modifications may be made thereto without departing from the spirit or scope of the appended
claims.
Accordingly, the preceding merely illustrates the principles of the invention, It will be
appreciated that those skilled in the art will be able to devise various arrangements which,
gh not itly described or shown herein, embody the principles of the invention and are
included within its spirit and scope. rmore, all examples and conditional language recited
herein are principally intended to aid the reader in understanding the principles of the invention
and the concepts contributed by the ors to furthering the art, and are to be construed as
being without tion to such specifically recited examples and conditions. Moreover, all
statements herein reciting principles, aspects, and embodiments of the invention as well as
specific examples thereof, are intended to encompass both structural and functional equivalents
thereof. Additionally, it is intended that such equivalents include both currently known
equivalents and equivalents developed in the future, i.e., any ts developed that perform the
same function, regardless of structure. The scope of the present invention, therefore, is not
intended to be limited to the embodiments shown and described herein. Rather, the scope and
spirit of present invention is embodied by the appended claims.
Claims (15)
1. Use of a procoagulant amount of a non—anticoagulant sulfated polysaccharide (NASP) selected from the group consisting of N—acetyl-heparin (NAH), N-acetyl—de-O-sulfated— n (NA—de—o-SH), de-N—sulfated—hepan'n (De-NSH), de—N—sulfated—acetylated-heparin (De—NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin—derived oligosaccharides (HDO), pentosan polysulfate (PPS), fucoidans, sulfated maltopentoses, sulfated beta-cyclodextrins, sulfated 6~Carboxyicodextrin in combination with chitosan and ain in the manufacture of a medicament for ing blood coagulation in a subject.
2. The use according to Claim 1, wherein the amount of NASP formulated for administration to the subject ranges from 0.01 mg/kg to about 100 mg/kg.
3. The use according to any of Claims 1—2, n the NASP is a naturally occurring synthetic NASP.
4. The use according to any of Claims 1-3, wherein the NASP is a naturally occurring NASP ed from the group ting of N—acetyl-heparin (NAH), N—acetyl-de-O- ed-heparin (NA—de-o—SH), de—N—sulfated—heparin (De-NSH), de-N—sulfated—acetylated— he- parin (De-NSAH), ate~oxidized heparin (POH), chemically sulfated rin (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan polysulfate (PPS) and fucoidans, and combinations thereof.
5. The use according to any of Claims 1—3, wherein the NASP is a synthetic NASP selected from the group consisting of sulfated oligomers, sulfated pentoses, sulfated hexoses or sulfated extrins.
6. The use according to any of Claims 1—5, wherein the medicament further comprises one or more factors ed from the group consisting of factor XI, factor XII, prekallikrein, high molecular weight kininogen (HMWK), factor V, factor VII, factor VIII, factor IX, factor X, factor XIII, factor II, von Willebrands factor, tissue factor, factor Vlla, factor Va, and factor Xa, factor IXa, factor Xla, factor Xlla, and VIIIa.
7. The use according to any of Claims 1—6, wherein the subject: (a) has a bleeding disorder selected from the group ting of a chronic or acute bleeding disorder, a ital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder; or (b) is in need of enhanced blood coagulation because of prior administration of an anticoagulant; or (c) is in need of enhanced blood coagulation e of a surgical or other invasive procedure.
8. The use according to any of Claims 1-7, wherein the ment inhibits TFPI activity in the subject.
9. The use according to any one of claims 1-8, wherein the ratio of chitosan to bromelain is sufficient to enhance tion 2-fold or greater than would be achieved by the sum of an or bromelain individually.
10. The use according to any one of claims 1-9, n the amount of chitosan formulated for administration to the subject is about 0.73% to about 3% and the amount of bromelain formulated for administration to the subject is about 0.05 mg/mL to about 0.5 mg/mL.
11. An oral dosage composition comprising: (a) a pro—coagulant amount of a non—anticoagulant sulfated polysaccharide (NASP) selected from the group consisting of N-acetyl~heparin (NAH), N—acetyl—de—O- sulfated—heparin (NA-de-o-SH), de-N~sulfated—heparin (De—NSH), de—N—sulfated-acetylated— heparin (De—NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically ed alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan polysulfate (PPS), ans, sulfated maltopentoses, sulfated beta-cyclodextrins, sulfated 6-Carboxyicodextrin; (b) chitosan and bromelain; and (c) an oral dosage delivery vehicle; wherein the oral dosage composition is in unit dosage form.
12. The oral dosage composition according to claim 11, wherein the ratio of chitosan to bromelain is sufficient to enhance permeation 2—fold or r than would be achieved by the sum of chitosan or bromelain individually.
13. The oral dosage composition according to claim 11, wherein the amount of an formulated for administration to the subject is about 0.3% to about 3% and the amount of bromelain formulated for administration to the t is about 0.05 mg/rnL to about 0.5 mg/mL.
14. The use of a procoagulant amount of a non—anticoagulant sulfated ccharide (NASP) in combination with chitosan and bromelain according to any one of claims 1 to 10, substantially as described herein.
15. An oral dosage composition according to any one of claims 11 to 13, substantially described herein. PCTIU
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509514P | 2011-07-19 | 2011-07-19 | |
US61/509,514 | 2011-07-19 | ||
PCT/US2012/047248 WO2013012954A2 (en) | 2011-07-19 | 2012-07-18 | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ618786A NZ618786A (en) | 2016-03-31 |
NZ618786B2 true NZ618786B2 (en) | 2016-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012284048B2 (en) | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides | |
JP5232470B2 (en) | Method for treating bleeding disorders using sulfated polysaccharides | |
ES2683948T3 (en) | Methods of procedure for purification of fucoidane from seaweed extracts | |
AU2011205271B2 (en) | Methods and compositions for treating bleeding disorders | |
AU2013215237B2 (en) | Non-anticoagulant sulfated or sulfonated polysaccharides | |
JPH0819001B2 (en) | Drugs, food products and compositions that suppress cholesterol absorption | |
AU2014242354B2 (en) | Resorption enhancers as additives to improve the oral formulation of low molecular weight heparins | |
US20130101574A1 (en) | Methods of using thrombin peptide derivatives | |
NZ618786B2 (en) | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides | |
JP2015504925A (en) | Non-anticoagulant sulfated or sulfonated synthetic polymer |